

**NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ
ANTAGONISTS**

FIELD OF THE INVENTION

5

The present invention relates to new phenylsulfamoyl benzamide derivatives of formula (I) and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof which are useful in the treatment or prevention of painful and inflammatory processes. The present invention also relates to the processes for producing compounds of formula (I) and to pharmacological compositions containing the same.

10

BACKGROUND OF THE INVENTION

15

Kinins are endogenous peptides formed in plasma and peripheral tissues in response to tissue injury or infection following catalytic cleavage of kininogens by kallikrein enzymes. Kinins play an important role in the pathophysiological processes accompanying pain and inflammation. Their biological actions are mediated by two G-protein coupled membrane receptors, denoted B1 and B2. Both B1 and B2 receptors have been cloned [*Biochem. Biophys. Res. Commun.*, **184** (1992) 260-268 and *J. Biol. Chem.*, **269** (1994) 21583-21586] and the mechanisms regulating their expression, self-maintenance and signalling function is under intensive investigations [*Mol. Pharmacol.*, **56** (1999) 325-333 and *J. Cell. Physiol.* **193** (2002) 275-286].

20

The first set of kinins, bradykinin (BK) and kallidin (LysBK) preferentially act through stimulation of constitutively expressed and rapidly desensitising B2 receptors, which are widely distributed in many tissues. On the other hand, their active carboxypeptidase metabolites, the second set of kinins, desArg⁹BK (DABK) and LysdesArg⁹BK (LysDABK) activate inducible and non-desensitising B1 receptors, which are rarely expressed under non-pathological conditions. Generally B1 receptors rapidly appear after injuries of various natures (tissue trauma, infections, *etc.*). Thus the

25

30

-2 -

B1 receptor up-regulation appears to be part of a generalized response that includes the local co-expression (eventually up-regulation) of enzymes, receptors, autacoids, cytokines and chemokines that notoriously play key roles in the early and late responses of tissues to various types of injury.

5 In animal models it has been demonstrated that there is a switch in dominance of function from B2 to B1 in chronic inflammatory states. While the B2 receptor is implicated in the acute phase of the inflammatory and pain response, the B1 receptor is involved in the chronic phase of this response. The involvement of kinin receptors in inflammation and pain transduction has been supported by the results of studies on mice
10 lacking bradykinin B1 receptors. B1 receptor deficient mice are different from wild-type mice in sensory functions, exhibiting increased analgesic thresholds to noxious chemical and heat stimuli, and drastic reduction in the accumulation of polymorphonuclear leukocytes at sites of inflammation [*PNAS*, **97** (2000) 8140-8145 and *Neuropharmacology* **41** (2001) 1006-1012]. Furthermore the most original finding
15 in B1 receptor deficient mice was the direct evidence for a role of central kinin receptors in nociception suggesting that the hypoalgesia seen in B1-receptor knockout mice is partly due to reduced central sensitisation in the spinal cord. However, apart from the above changes B1 knockout mice were apparently normal without any apparent pathological changes.

20 Apart from the evidence of basal expression of B1 receptors on the periphery recently more and more evidence shows that B1 receptors are constitutively expressed 'centrally' in some neuronal elements, including the spinal cord and some higher structures as well. The function of these receptors is unclear but they have been implicated in pain transmission and hyperalgesia. Therefore, B1 receptor antagonists are
25 believed to be useful in alleviating pain not only via peripheral sites but also to have possibly broader spectrum of analgesic effects if they block central B1 receptors as well [*NeuroReport* **11** (2000) 4003-4005; *NeuroReport*, **12** (2001) 2311-2313; *Neuroscience* **107** (2001) 665-673 and *Neuroscience Letters* **294** (2000) 175-178].

On the basis of scientific data bradykinin receptors are involved in mediation of
30 pain and hyperalgesia in several ways. B1 receptor antagonists may have diverse modes of action. They have (1) indirect ('peripheral') effects on the nociceptors via inhibition of release of other algogenic mediators. N.B. B1 receptors appear upon inflammatory

-3 -

induction on cells adjacent to sensory neurones (macrophages, fibroblasts or endothelial cells) are involved in releasing mediators (prostaglandins, cytokines and nitric oxide) that sensitize or activate the nociceptors. (2) direct ('peripheral') effects on nociceptors expressing B1 receptors (constitutively) or upon induction and (3) 'central' effects on pain processing in the superficial dorsal horn of spinal cord.


Therefore, an orally active non-peptide bradykinin B1 receptor antagonist could be a potential therapeutic agent in the treatment of chronic inflammatory pain.

Several patents and patent applications describe bradykinin B1 receptor antagonists which have different chemical structures. Such documents are for instance the following international patent applications: WO200075107, WO02076964, WO04054584, WO02099388, WO05004810.

SUMMARY OF THE INVENTION

We have found a class of benzamide derivatives which have high affinity for bradykinin B1 receptors and selectivity over bradykinin B2 receptors. The selectivity is particularly important as the undesired side effects of the compounds are much less pronounced.

The present invention relates to new phenylsulfamoyl benzamide derivatives of formula (I)



(I)

wherein

-4 -

- R^1 is hydrogen atom or C_1 - C_4 alkyl group;
 R^2 is selected from (1) hydrogen atom; (2) C_1 - C_6 straight or branched alkyl group;
 (3) $-(CH_2)_n-NH_2$; (4) $-(CH_2)_n-OH$; (5) $-(CH_2)_n-CO-NH_2$; (6) $-(CH_2)_n-COOR^c$;
 (7) benzyl optionally substituted with one or more hydroxy group or halogen
 5 atom; or
 R^1 , R^2 and the carbon atom to which they are both attached together form a 3-7
 membered cycloalkyl ring;
 R^3 is (1) hydrogen atom, (2) C_1 - C_8 straight or branched alkyl group, optionally
 substituted with one or more substituents independently selected from amino,
 10 hydroxy, 1*H*-imidazol-4-yl, $-NR^aR^b$, $-COOR^c$, $-NH-C(=NH)-NH_2$, $-CO-NH_2$,
 group;
 R^4 is (1) hydrogen atom, (2) $-(CH_2)_n-NR^aR^b$ group; (3) $-(CH_2)_m-X-P$ group;
 R^5 , R^6 and R^7 are independently of each other hydrogen atom, halogen atom, cyano,
 nitro, amino, or amino substituted with one or more C_1 - C_4 alkyl group;
 15 trifluoromethyl; C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $-C(=O)-NH_2$, C_1 - C_4 alkoxycarbonyl,
 trifluoromethoxy or hydroxy group;
 R^8 is hydrogen atom or C_1 - C_4 alkyl group;
 Z is selected from (1) single bond; (2) oxygen atom; (3) CH_2 group; (4) CO group;
 (5) NR^c group; (6) S atom; (7) SO_2 group;
 20 n is an integer from 1 to 6;
 m is an integer from 0 to 6;
 X is selected from (1) single bond; (2) oxygen atom; (3) $-CO-NR^c$ group; (4) CO
 or SO_2 group;
 P is selected from (1) phenyl group, optionally substituted with one or more
 25 halogen atom, hydroxy, $-(CH_2)_m-CN$, $-O-CO-NR^cR^c$, $-NH-CO-R^c$, C_1 - C_4
 alkyl, C_1 - C_4 alkoxy, cyano, amino, [1,4']bipiperidiny-1'-yl or $-(CH_2)_n-NH-$
 $C(=NH)-NH_2$ group; (2) a saturated, partially unsaturated or aromatic 4-7
 membered ring containing 1-3 heteroatom selected from O, S, SO_2 and N;
 wherein said ring is optionally substituted with one or more halogen atom, oxo,
 30 hydroxy, cyano, amino, trifluoromethyl, $-NH-CO-R^c$, $-C(=NH)-NH_2$, C_1 - C_4
 alkyl, pyridin-4-yl, piperidin-1-yl or pyridine-2-yl group; (3) a saturated,
 partially unsaturated or aromatic 8-10 membered bicyclic ring system containing

-5 -

1-3 heteroatom selected from O, S, SO₂ and N; wherein said ring system is optionally substituted with one or more halogen atom, oxo, hydroxy, cyano, amino, -NH-CO-R^c, trifluoromethyl or C₁-C₄ alkyl group; (4) C₅-C₈ cycloalkyl group, optionally substituted with -(CH₂)_m-NR^aR^b group;

5 R^a and R^b are (1) hydrogen atom; (2) straight or branched C₁-C₆ alkyl group; (3) R^a, R^b and the nitrogen atom to which they are both attached together form a saturated, partially unsaturated or aromatic 4-7 membered ring containing 0-3 heteroatom (in addition to the nitrogen atom to which R^a and R^b attached) selected from O, S, SO₂ and N; wherein said ring is optionally substituted with one or more
10 halogen atom, oxo, cyano, hydroxy or C₁-C₄ alkyl group;

R^c is hydrogen atom or C₁-C₄ alkyl group;

and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof.


The invention also relates to the pharmaceutical compositions containing the compounds of formula (I) or optical antipodes or racemates or salts or hydrates or
15 solvates thereof as active ingredient.

Furthermore objects of the present invention are the synthesis of compounds of formula (I), and the chemical and pharmaceutical manufacture of medicaments containing these compounds, as well as the methods of treatment with these compounds, which means administering to a mammal to be treated - including human -
20 effective amount/amounts of compounds of formula (I) of the present invention as such or as medicament.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to new bradykinin B1 receptor antagonist
25 phenylsulfamoyl benzamide derivatives of formula (I)

-6 -



(I)

wherein

- R^1 is hydrogen atom or C_1 - C_4 alkyl group;
- 5 R^2 is selected from (1) hydrogen atom; (2) C_1 - C_6 straight or branched alkyl group; (3) $-(CH_2)_n-NH_2$; (4) $-(CH_2)_n-OH$; (5) $-(CH_2)_n-CO-NH_2$; (6) $-(CH_2)_n-COOR^c$; (7) benzyl optionally substituted with one or more hydroxy group or halogen atom; or
- R^1 , R^2 and the carbon atom to which they are both attached together form a 3-7
- 10 membered cycloalkyl ring;
- R^3 is (1) hydrogen atom, (2) C_1 - C_8 straight or branched alkyl group, optionally substituted with one or more substituents independently selected from amino, hydroxy, 1*H*-imidazol-4-yl, $-NR^aR^b$, $-COOR^c$, $-NH-C(=NH)-NH_2$, $-CO-NH_2$, group;
- 15 R^4 is (1) hydrogen atom, (2) $-(CH_2)_n-NR^aR^b$ group; (3) $-(CH_2)_m-X-P$ group;
- R^5 , R^6 and R^7 are independently of each other hydrogen atom, halogen atom, cyano, nitro, amino, or amino substituted with one or more C_1 - C_4 alkyl group; trifluoromethyl; C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $-C(=O)-NH_2$, C_1 - C_4 alkoxy carbonyl, trifluoromethoxy or hydroxy group;
- 20 R^8 is hydrogen atom or C_1 - C_4 alkyl group;
- Z is selected from (1) single bond; (2) oxygen atom; (3) CH_2 group; (4) CO group; (5) NR^c group; (6) S atom; (7) SO_2 group;
- n is an integer from 1 to 6;
- m is an integer from 0 to 6;

-7-

X is selected from (1) single bond; (2) oxygen atom; (3) $-\text{CO}-\text{NR}^{\circ}$ group; (4) CO or SO_2 group;

P is selected from (1) phenyl group, optionally substituted with one or more halogen atom, hydroxy, $-(\text{CH}_2)_m-\text{CN}$, $-\text{O}-\text{CO}-\text{NR}^{\circ}\text{R}^{\circ}$, $-\text{NH}-\text{CO}-\text{R}^{\circ}$, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkoxy, cyano, amino, [1,4']bipiperidiny-1'-yl or $-(\text{CH}_2)_n-\text{NH}-\text{C}(=\text{NH})-\text{NH}_2$ group; (2) a saturated, partially unsaturated or aromatic 4-7 membered ring containing 1-3 heteroatom selected from O, S, SO_2 and N; wherein said ring is optionally substituted with one or more halogen atom, oxo, hydroxy, cyano, amino, trifluoromethyl, $-\text{NH}-\text{CO}-\text{R}^{\circ}$, $-\text{C}(=\text{NH})-\text{NH}_2$, $\text{C}_1\text{-C}_4$ alkyl, pyridin-4-yl, piperidin-1-yl or pyridine-2-yl group; (3) a saturated, partially unsaturated or aromatic 8-10 membered bicyclic ring system containing 1-3 heteroatom selected from O, S, SO_2 and N; wherein said ring system is optionally substituted with one or more halogen atom, oxo, hydroxy, cyano, amino, $-\text{NH}-\text{CO}-\text{R}^{\circ}$, trifluoromethyl or $\text{C}_1\text{-C}_4$ alkyl group; (4) $\text{C}_5\text{-C}_8$ cycloalkyl group, optionally substituted with $-(\text{CH}_2)_m-\text{NR}^a\text{R}^b$ group;

R^a and R^b are (1) hydrogen atom; (2) straight or branched $\text{C}_1\text{-C}_6$ alkyl group; (3) R^a , R^b and the nitrogen atom to which they are both attached together form a saturated, partially unsaturated or aromatic 4-7 membered ring containing 0-3 heteroatom (in addition to the nitrogen atom to which R^a and R^b attached) selected from O, S, SO_2 and N; wherein said ring is optionally substituted with one or more halogen atom, oxo, cyano, hydroxy or $\text{C}_1\text{-C}_4$ alkyl group;

R° is hydrogen atom or $\text{C}_1\text{-C}_4$ alkyl group;

and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof.

The invention also relates to the pharmaceutical compositions containing the compounds of formula (I) or optical antipodes or racemates or salts or hydrates or solvates thereof as active ingredient.

Furthermore objects of the present invention are the synthesis of compounds of formula (I), and the chemical and pharmaceutical manufacture of medicaments containing these compounds, as well as the methods of treatment with these compounds, which means administering to a mammal to be treated - including human - effective amount/amounts of compounds of formula (I) of the present invention as such or as medicament.

The term "halogen" substituent denotes fluorine, chlorine, bromine or iodine atoms. The term C₁-C₄ alkyl group used in the present description denotes methyl, ethyl, normal- and isopropyl and different butyl groups. These C₁-C₄ alkyl groups can be in the C₁-C₄ alkoxy groups.

5 The saturated, partially unsaturated or aromatic 4-7 membered heterocyclic ring in the meaning of R^a and R^b can be *e.g.* piperidine, pyrrolidine, piperazine, homopiperazine, imidazole, triazole, tetrazole, morpholine, thiomorpholine and the like.

 The saturated, partially unsaturated or aromatic 4-7 membered heterocyclic ring in the meaning of P can be *e.g.* piperidine, pyrrolidine, pyridine, piperazine,
10 homopiperazine, imidazole, triazole, tetrazole, morpholine, thiomorpholine and the like.

 The saturated, partially unsaturated or aromatic 8-10 membered bicyclic ring system in the meaning of P can be *e.g.* indole, benzimidazole, benzo[1,3]dioxol, benzothiazole and the like.

 The invention relates also to the salts of compounds of formula (I) formed with
15 acids or bases.

 Both organic and inorganic acids can be used for the formation of acid addition salts. Suitable inorganic acids can be *e.g.* hydrochloric acid, sulfuric acid and phosphoric acid. Representatives of monovalent organic acids can be *e.g.* formic acid, acetic acid, trifluoroacetic acid, propionic acid, and different butyric acids, valeric acids
20 and capric acids. Representatives of bivalent organic acids can be *e.g.* oxalic acid, malonic acid, maleic acid, fumaric acid and succinic acid. Other organic acids can also be used, such as hydroxy acids *e.g.* citric acid, tartaric acid, or aromatic carboxylic acids *e.g.* benzoic acid or salicylic acid, as well as aliphatic and aromatic sulfonic acids *e.g.* methanesulfonic acid and p-toluenesulfonic acid. Especially valuable group of the acid
25 addition salts is in which the acid component itself does not have therapeutical effect in the applied dose or it does not have unfavorable influence on the effect of the active ingredient. These acid addition salts are pharmaceutically acceptable acid addition salts. The reason why acid addition salts, which do not belong to the pharmaceutically acceptable acid addition salts belong to the present invention is, that in given case they
30 can be advantageous in the purification and isolation of the desired compounds.


 Among the salts formed with bases especially important are the salts formed with alkali metals, *e.g.* sodium, potassium, alkaline-earth metals, *e.g.* calcium and

magnesium, as well as with ammonia or organic amines. The latter bases can have further substituents, *e.g.* hydroxy or amino groups, which can influence *e.g.* the solubility and the handling of the product. The salts formed with bases are pharmaceutically acceptable base addition salts.

5 According to the invention the compounds of formula (I) can be synthesized by one of the following methods:


Method a)

An amine derivative of formula (II)




(II)

- wherein the meaning of R^5 , R^6 and R^7 is as described above for the formula (I) – is reacted with the sulfonyl chloride of formula (III)



(III)


15 then the so obtained phenylsulfamoyl benzoic acid derivative of formula (IV)



(IV)

-10 -

– wherein the meaning of R^5 , R^6 and R^7 is as defined above – is reacted with an amine derivative of formula (V)



5

(V)

– wherein the meaning of R^1 , R^2 , R^3 , R^4 and R^5 is as defined above – and the obtained phenylsulfamoyl benzamide derivative of formula (I) in given case can be transformed into an other compound of formula (I) by introducing new substituents and/or modifying or removing the existing ones, and/or salt formation and/or liberating the compound from salts.


10

Method b)

The phenylsulfamoyl benzoic acid derivative of formula (IV) – obtained according to the method described in method a) – is reacted with an amino acid derivative of formula

15


(VI)



(VI)


– wherein the meaning of R^1 , R^2 and R^5 is as defined above, and R is C_1 - C_4 alkyl group – and the so obtained compound of formula (VII)

-11 -




(VII)

- wherein the meaning of R^1 , R^2 , R^5 , R^6 , R^7 , R^8 and R is as defined above – is
 5 hydrolyzed to furnish a carboxylic acid derivative of formula (VIII)



(VIII)

- wherein the meaning of R^1 , R^2 , R^5 , R^6 , R^7 and R^8 is as defined above – finally the
 10 latter is reacted with an amine derivative of formula (IX)



(IX)

- wherein the meaning of R^3 and R^4 is as defined above - and the obtained
 phenylsulfamoyl benzamide derivative of formula (I) in given case can be transformed
 15 into an other compound of formula (I) by introducing new substituents and/or

-12 -

modifying or removing the existing ones, and/or salt formation and/or liberating the compound from salts.

The sulfonylation reaction is preferably carried out in a proper solvent, preferably in the presence of a base. The reactions are followed by thin layer chromatography. The necessary reaction time is 6-20 h. The work-up of the reaction mixture can be carried out by different methods.

a) The reaction mixture is concentrated and the product is isolated by crystallization or extraction. If the crude product is not pure enough, then column chromatography can be used for the purification of it. The column chromatography is carried out either on normal phase using Kieselgel 60 as adsorbent and different solvent systems, *e.g.* n-hexane/ethyl acetate, chloroform/methanol, dichloromethane/ethyl acetate or chloroform/acetone as eluents, or on reversed phase using YMC-Pack ODS-AQ type packings (produced by YMC) and acetonitrile/water/trifluoroacetic acid or acetonitrile/water/acetic acid as eluent.

b) The reaction mixture is poured into ice-water and the product is isolated by filtration or extraction. The crude product is crystallized or purified by column chromatography as described above. The structures of the products are determined by IR, NMR and mass spectrometry.

The amide bond formation is preferably carried out by preparing an active derivative from a carboxylic acid of formula (IV) or (VIII) which is reacted with an amine of formula (V) or (IX), respectively, preferably in the presence of a base.

The transformation of a carboxylic acid into an active derivative can be carried out *in situ* during the amide bond formation in a proper solvent (*e.g.* dimethylformamide, acetonitrile, chlorinated hydrocarbons or hydrocarbons or the mixture thereof). The active derivatives can be acid chlorides (*e.g.* prepared from carboxylic acid with thionyl chloride), mixed anhydrides (*e.g.* prepared from carboxylic acid with isobutyl chloroformate in the presence of a base, *e.g.* triethylamine), active esters (*e.g.* prepared from carboxylic acid with hydroxybenzotriazol (HOBt) and dicyclohexyl-carbodiimide (DCC) or O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) in the presence of a base *e.g.* triethylamine). The active derivatives can be prepared at a temperature in the range of 0

°C to room temperature. A proper amine of formula (V) or (IX) is added as a base or as a salt formed with inorganic acid to the so obtained solution or suspension in the presence of a base, *e.g.* triethylamine, needed for the liberation of the amine. The condensation reactions are followed by thin layer chromatography. The necessary
5 reaction time is 6-20 h. The work-up of the reaction mixture can be carried out by different methods.

a) The reaction mixture is concentrated, and the residue is crystallized or extracted with a proper organic solvent and in given case purified by column chromatography. The column chromatography is carried out on normal phase using
10 Kieselgel 60 as adsorbent and different solvent systems, *e.g.* toluene/methanol, chloroform/methanol or toluene/acetone, as eluents or on reversed phase using YMC-Pack ODS-AQ type packings (produced by YMC) and acetonitrile/water/trifluoroacetic acid or acetonitrile/water/acetic acid as eluent.

b) The reaction mixture is directly purified by column chromatography as
15 described above to yield the pure product.

The structures of the products are determined by IR, NMR and mass spectrometry.

The obtained benzamide derivatives of formula (I) – independently from the method of preparation – in given case can be transformed into another compound of
20 formula (I) by introducing further substituents and/or modifying and/or removing the existing ones, and/or formation of salts with acids and/or liberating the benzamide derivative of formula (I) from the obtained acid addition salts by treatment with a base and/or the free sulfonamide derivative of formula (I) can be transformed into a salt by treatment with a base.

25 The compounds of formula (I) containing free hydroxy group can be transformed into acyloxy or sulfoxy derivatives with different acylating or sulfonylating agents. The reactions can be carried out for example in chlorinated hydrocarbons using acid chloride or acid anhydride as acylating agent in the presence of a base (*e.g.* triethylamine or sodium carbonate). The sulfonamide derivatives of formula (I)
30 containing a nitro group can be transformed into amines by reduction and the amines can be further reacted to give acid amides as described for the acylation of hydroxy groups or carbamate derivatives can be synthesized. Ester groups can be hydrolyzed and

the obtained free carboxylic acids can be transformed into amides by reacting with proper amine derivatives. N-(*tert*-Butoxycarbonyl) group can be cleaved by organic or inorganic acids (*e.g.* trifluoroacetic acid or hydrogen chloride). Free amino groups can be transformed into guanidino groups. Cyano groups can be transformed into amide, N-
5 hydroxy-amidine or different N-containing heterocyclic groups.

Most of the amino acids of formula (VI) and amines of formula (IX) are either commercially available or can be synthesized by different known methods. The syntheses of some new amines of formula (IX) are described in the Examples. Following these procedures the other amines of formula (IX) can also be prepared. The
10 amines of formula (V) are new.

The compounds of the present invention as well as their pharmaceutically acceptable salts or hydrates or solvates can be used as such or suitably in the form of pharmaceutical compositions. These compositions (drugs) can be in solid, liquid or
15 semiliquid form and pharmaceutical adjuvant and auxiliary materials can be added, which are commonly used in practice, such as carriers, excipients, diluents, stabilizers, wetting or emulsifying agents, pH- and osmotic pressure-influencing, flavoring or aromatizing, as well as formulation-promoting or formulation-providing additives.

The dosage required to exert the therapeutical effect can vary within wide limits
20 and will be fitted to the individual requirements in each of the particular case, depending on the stage of the disease, the condition and the bodyweight of the patient to be treated, as well as the sensitivity of the patient against the active ingredient, route of administration and number of daily treatments. The actual dose of the active ingredient to be used can safely be determined by the attending physician skilled in the art in the
25 knowledge of the patient to be treated.

The pharmaceutical compositions containing the active ingredient according to the present invention usually contain 0.01 to 100 mg of active ingredient in a single dosage unit. It is, of course possible that the amount of the active ingredient in some compositions exceeds the upper or lower limits defined above.

30 The solid forms of the pharmaceutical compositions can be *e.g.* tablets, dragées, capsules, pills or lyophilized powder ampoules useful for the preparation of injections. Liquid compositions are the injectable and infusable compositions, fluid medicines,

packing fluids and drops. Semiliquid compositions can be ointments, balsams, creams, shaking mixtures and suppositories.

For the sake of a simple administration it is suitable if the pharmaceutical compositions comprise dosage units containing the amount of the active ingredient to be administered once, or a few multiples or a half, third or fourth part thereof. Such dosage units are *e.g.* tablets, which can be powdered with grooves promoting the halving or quartering of the tablet in order to exactly administer the required amount of the active ingredient.

Tablets can be coated with an acid-soluble layer in order to assure the release of the active ingredient content after leaving the stomach. Such tablets are enteric-coated. A similar effect can be achieved also by encapsulating the active ingredient.

The pharmaceutical compositions for oral administration can contain *e.g.* lactose or starch as excipients, sodium carboxymethylcellulose, methylcellulose, polyvinyl pyrrolidone or starch paste as binders or granulating agents. Potato starch or microcrystalline cellulose is added as disintegration agents, but ultraamylpectin or formaldehyde casein can also be used. Talcum, colloidal silicic acid, stearin, calcium or magnesium stearate can be used as antiadhesive and lubricants.

The tablets can be manufactured *e.g.* by wet granulation, followed by pressing. The mixed active ingredients and excipients, as well as in given case part of the disintegrants are granulated with an aqueous, alcoholic or aqueous alcoholic solution of the binders in an appropriate equipment, then the granulate is dried. The other disintegrants, lubricants and antiadhesive agents are added to the dried granulate, and the mixture is pressed to a tablet. In given case the tablets are made with halving groove to ease the administration.

The tablets can be made directly from the mixture of the active ingredient and the proper auxiliaries by pressing. In given case, the tablets can be coated by using additives commonly used in the pharmaceutical practice, *e.g.* stabilizers, flavoring, coloring agents, such as sugar, cellulose derivatives (methyl- or ethylcellulose, sodium carboxymethylcellulose, etc), polyvinyl pyrrolidone, calcium phosphate, calcium carbonate, food coloring agents, food laces, aroma agents, iron oxide pigments, etc. In the case of capsules the mixture of the active ingredient and the auxiliaries is filled into capsules.

-16 -

Liquid oral compositions, *e.g.* suspensions, syrups, elixirs can be made by using water, glycols, oils, alcohols, coloring and flavoring agents.

For rectal administration the composition is formulated in suppositories or clysters. The suppository can contain beside the active ingredient a carrier, so called
5 adeps pro suppository. Carriers can be vegetable oils, such as hydrogenated vegetable oils, triglycerides of C₁₂-C₁₈ fatty acids (preferably the carriers under the trade name Witepsol). The active ingredient is homogeneously mixed with the melted adeps pro suppository and the suppositories are moulded.

For parenteral administration the composition is formulated as injection solution.
10 For manufacturing the injection solution the active ingredients are dissolved in distilled water and/or in different organic solvents, such as glycolethers, in given case in the presence of solubilizers, *e.g.* polioxyethylensorbitane-monolaurate, -monooleate, or monostearate (Tween 20, Tween 60, Tween 80). The injection solution can also contain different auxiliaries, such as conserving agents, *e.g.* ethylenediamine tetraacetate, as well
15 as pH adjusting agents and buffers and in given case local anaesthetic, *e.g.* lidocain. The injection solution containing the active ingredient of the invention is filtered before it is filled into ampoules, and it is sterilized after filling.

If the active ingredient is hygroscopic, then it can be stabilized by liophylization.

20 Utilities

The compounds of the present invention are bradykinin receptor antagonists, in particular selective bradykinin B1 receptor antagonists, consequently are useful in the
25 treatment or prevention of painful and inflammatory processes. The compounds would be effective in the treatment of pain including, *e.g.*, chronic pain, particularly inflammatory pain, hyperalgesia, bone and joint pain (osteoarthritis), repetitive motion pain, myofascial pain (muscular injury, fibromyalgia), visceral pain (ulcerative colitis, pancreatitis, cystitis, uveitis), perioperative pain (general surgery, gynecological),
30 postoperative pain (postsurgical pain syndrome), posttraumatic pain (*e.g.* sprains or fracture), neuropathic pain (postherpetic neuralgia, nerve injury, phantom limb pain, mononeuropathy, polyneuropathy) dental pain, and cancer pain. Furthermore for the

-17 -

treatment of pain associated with angina, menstruation, diabetic vasculopathy, post capillary resistance or diabetic symptoms associated with insulinitis (*e.g.* hyperglycemia, diuresis, proteinuria and increased nitrite and kallikrein urinary excretion), diabetic hyperalgesia. Moreover the compounds may be used for the treatment angioedema, atherosclerosis, septic shock *e.g.* as anti-hypovolemic and/or anti-hypotensive agents, and sepsis. They may be used as smooth muscle relaxants for the treatment of spasm of the gastrointestinal tract or uterus. Further, the compounds of this invention can additionally be used to treat inflammatory skin disorders, such as psoriasis and eczema, and skin injuries including burning and sunburning (UV-erythema and pain). The compounds may be used to treat inflammatory pain of varied origins (*e.g.* rheumatoid arthritis, rheumatic disease, tenosynovitis, liver disease, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, nephritis, allergic rhinitis, vasomotor rhinitis, uveitis, gingivitis), allergies. Such compounds may be used therapeutically to treat inflammatory airways disease *e.g.* chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis, pneumonia, asthma. They may be used to control, restrict or reverse airways hyperreactivity in asthma, to treat intrinsic and extrinsic asthma including allergic asthma (atopic or non-atopic), occupational asthma, viral or bacterial exacerbated asthma, other non-allergic asthmas, "wheezy-infant syndrome", as well as exercise-induced bronchoconstriction. They may be effective against pneumoconiosis, including aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis. Additionally, they may be effective in some neurological disorders, *e.g.* against multiple sclerosis, Alzheimer's disease, epilepsy, cerebral edema, headache including cluster headache, migraine including prophylactic and acute use, as well as closed head trauma.

Biological evaluation

Functional assay:

Assessment of antagonist potency at B1 and B2 receptors *in vitro* by measurement of cytosolic calcium ion concentration with a plate reader fluorimeter in cells expressing recombinant human B1 or B2 receptors

Cell culture

Chinese hamster ovary (CHO) cells stably expressing recombinant human B1 (CHO-B1, Euroscreen) or B2 (CHO-B2, Perkin-Elmer) receptors were cultured in
5 Dulbecco's Modified Eagle's Medium (DMEM) containing 10% Fetal Calf Serum (FCS), 100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.25 µg/ml amphotericin B, 1% Minimum Essential Medium Eagle (MEM), non essential amino acid solution, 600 µg/ml G418, 1% pyruvate (for the B2 cell line). Cells were kept at 37°C in a humidified incubator in an atmosphere of 5% CO₂/95% air and were passaged 1:4 three times a
10 week. Cells were plated at $1.5\text{--}2.5 \times 10^4$ cell/well on standard 96-well microplates, measurements of cytosolic calcium ion concentration ($[\text{Ca}^{2+}]_i$) were carried out 1-2 days after cell plating.

Fluorimetric measurement of cytosolic calcium concentration

15

Measurements of $[\text{Ca}^{2+}]_i$ were carried out on CHO-B1 and CHO-B2 cells stably expressing human B1 and B2 receptors, respectively. Cells were grown in standard 96-well microplates and before the measurement were loaded with a fluorescent Ca^{2+} -sensitive dye, fluo-4/AM (2 µM): after removing the culture medium the dye was added
20 to the cells (dissolved in assay buffer: 145 mM NaCl, 5 mM KCl, 2 mM MgCl₂, 2 mM CaCl₂, 10 mM HEPES, 20 mM D-glucose, 2 mM probenecid, 100 µl/well) and cells were incubated at 37°C in a humidified incubator in an atmosphere of 5% CO₂/95% air for 40-120 min. To stop dye loading cells were washed twice with assay buffer. After washing, various concentrations of the test compounds (diluted in extracellular medium
25 from a DMSO stock solution, final DMSO concentration was <0.1%) or buffer were added to each well depending on the experimental setup. After incubation at 37°C for 20-25 min. baseline and agonist-evoked changes of $[\text{Ca}^{2+}]_i$ were measured column by column with a plate reader fluorimeter (Fluoroskan Ascent, Labsystems). Excitation and detection of emission was carried out from the bottom of the plate. Filters used for Fluo-
30 4: excitation filter – 485 nm, emission filter – 538 nm. The whole measurement process was performed at 37°C and was controlled by custom software. Inhibitory potency of

-19 -

the test compounds was assessed by measuring the reduction in the agonist-evoked $[Ca^{2+}]_i$ -elevation in the presence of different concentrations of the compounds. The agonists were LysDABK for CHO-B1, and bradykinin for CHO-B2 cells. Agonists were applied at an EC_{80} concentration, the EC_{80} -values were derived from daily
 5 determined dose-response curves. Fluorescence data were expressed as $\Delta F/F$ (fluorescence change normalized to baseline). All treatments on a single plate were measured in multiple wells. Data from all wells with the same treatment were averaged and the average values were used for analysis. Inhibitory potency of a compound at a single concentration point was expressed as percent inhibition of the control agonist
 10 response. Sigmoidal concentration-inhibition curves were fitted to the data (derived from at least three independent experiments) and IC_{50} -values were determined as the concentration that produces half of the maximal inhibition caused by the compound.

The examined reference compounds measured in functional and binding tests are
 15 the following:

- 1) 4-{2-[(2,2-diphenyl-ethyl)-amino]-5-{4-[4-(4-methyl-1-piperazinyl)-carbonyl]-1-piperidinyl]-sulfonyl}-benzoyl}-morpholine (NVP-SAA164, Br. J. Pharmacol. **144** (2005) 889-899); K_i 8 nM; IC_{50} : 33 nM;
- 2) (R)-N-[2,3-dihydro-2-oxo-5-(2-phenyl-ethyl)-1-propyl-1H-1,4-benzodiazepin-3-yl]-
 20 N'-{4-[4-(4-pyridinyl)-1-piperazinyl]-phenyl}-urea (J. Med. Chem. **46** (2003) 1803-1806); K_i 0.59 nM; IC_{50} 1.9 nM;
- 3) N-[4-(4'-bipiperidin)-1'-ylphenyl]-N'-[(3R)-2,3-dihydro-5-(4-methyl-phenyl)-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]-urea (J. Med. Chem. **46** (2003) 1803-1806);
 K_i 13.4 nM; IC_{50} 64.5 nM

25 The K_i and IC_{50} data measured by us for the reference compounds are in good agreement with the data given in the literature.

In Table 1 the most effective compounds of this invention measured in functional assay are listed.

Table 1

Number of example	B1 func.	Number of example	B1 func.
1	++++	25	++++
2	++++	27	++++
3	++++	28	++++
4	++++	29	++++
5	+++	30	++++
6	++++	31	++++
7	++++	37	++++
8	++++	39	++++
10	++++	48	++++
11	+++	49	++++
12	++++	50	++++
13	++++	54	++++
14	++++	56	++++
15	++++	60	++++
16	++++	61	++++
18	++++	62	++++
22	++++	63	++++
23	++++	66	++++

+ IC₅₀ > 0.5 µM+++ IC₅₀ is between 20 and 100 nM++ IC₅₀ is between 0.1 and 0.5 µM++++ IC₅₀ < 20 nM

5

Receptor binding assays**1. Human recombinant bradykinin B1 receptor binding**

10 Binding assays were carried out on human recombinant bradykinin₁ receptors (expressed in CHO cells) according to the Euroscreen Technical Data Sheet (Cat.No.:ES-091). 20µg protein/tube was incubated with [3,4-prolyl-3,4-³H(N)]-[Des-

Arg¹⁰] Kallidin as radioligand. Non specific binding was determined in the presence of 10 μ M Lys-des-Arg⁹-Bradykinin. The final incubation volume was 250 μ l. Samples were incubated for 15 min. at 25 °C then were rapidly vacuum filtered through GF/B filters presoaked for at least 1 h in 0.5 % PEI. Radioactivity was determined by liquid
 5 scintillation spectroscopy.

In Table 2 the most effective compounds of this invention measured in binding assay are listed.

Table 2

Number of example	B1 binding	Number of example	B1 binding
1	++++	29	++++
2	++++	30	++++
3	++++	31	++++
4	++++	35	++++
5	+++	37	++++
6	++++	39	++++
7	++++	43	++++
8	++++	48	++++
10	++++	49	++++
11	+++	50	++++
12	++++	54	++++
13	++++	56	++++
14	++++	59	++++
15	++++	60	++++
16	++++	61	++++
18	++++	62	++++
22	++++	63	++++
23	++++	66	++++
25	++++	73	++++
27	++++	103	++++
28	++++		

+ K_i > 0.5 μ M

+++ K_i is between 20 and 100 nM

-22 -

++ K_i is between 0.1 and 0.5 μM +++++ $K_i < 20 \text{ nM}$

2. Human recombinant bradykinin B2 receptor binding

Binding assays were carried out on human recombinant bradykinin2 receptors
 5 (expressed in CHO cells) according to the Receptor Biology Technical Data Sheet
 (Cat.No.:RBHB2M) with minor modifications. 8.4 μg protein/tube was incubated with
 [2,3,-prolyl-3,4- $^3\text{H}(\text{N})$]-Bradykinin as radioligand. Non specific binding was determined
 in the presence of 5 μM bradykinin. The final incubation volume was 200 μl . Samples
 10 were incubated for 90 min. at +4 $^\circ\text{C}$ then were rapidly vacuum filtered through GF/B
 filters presoaked for at least 1 h in 0.5 % PEI. Radioactivity was determined by liquid
 scintillation spectroscopy.

The compounds exhibited high affinity and selectivity (>50 fold) for the human
 B1 receptor over the human B2 receptor according to both functional and binding
 assays.

15 The synthesis of compounds and pharmaceutical compositions according to the
 invention is illustrated by the following not limiting Examples.

Reference Example 1

20 4-[(2-Amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

a) 4-[(2-Benzoyloxycarbonylamino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

A solution of Z-glycine (Aldrich) (1.95 g, 9.32 mmol), HOBt [1-
 hydroxybenzotriazol] (1.26 g, 9.32 mmol) and EDC hydrochloride [*N*-(3-
 25 dimethylaminopropyl)-*N'*-ethylcarbodiimide] (1.79 g, 9.32 mmol) in dry
 dimethylformamide (20 mL) was stirred at 0 $^\circ\text{C}$ for ten minutes before 4-aminomethyl-
 piperidine-1-carboxylic acid *tert*-butyl ester (Fluka) (2.0 g, 9.32 mmol) was added and
 the reaction mixture was stirred at room temperature overnight. The mixture was
 concentrated *in vacuo*, the residue was treated with saturated sodium hydrogencarbonate
 30 solution (50 mL), extracted with chloroform (3x50 mL), the combined organic layers
 were dried over sodium sulfate, filtered and concentrated. The residue was purified by
 column chromatography using Kieselgel 60 (0.040-0.063 mm) (Merck) as adsorbent,

and chloroform:methanol = 25:1 as eluent to yield 3.57 g (94.5 %) of the title compound as white amorphous solid. MS (EI) 428.2 (M+Na⁺).

b) 4-[(2-Amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

5 A stirred suspension of 4-[(2-benzyloxycarbonylamino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (3.57 g, 8.80 mmol) and 10 % Pd/C (0.36 g) in methanol : acetic acid : water 5:1:1 was hydrogenated at room temperature for 3 h. The catalyst was filtered off and the filtrate was concentrated *in vacuo*. The remaining crude material was purified by column chromatography using Kieselgel 60 (0.015-0.040
10 mm) (Merck) as adsorbent, and chloroform:methanol:ammonium hydroxide = 25:1:0.1 as eluent to yield 1.62 g (64.0 %) of the title compound as white amorphous solid. MS (EI) 294.3 (M+Na⁺).

Reference Example 2

15 **4-[2-(2-Amino-acetyl-amino)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester**

a) 4-[2-(2-Benzyloxycarbonylamino-acetyl-amino)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-(2-amino-ethyl)-piperidine-1-carboxylic acid *tert*-butyl ester [*Bioorg. Med. Chem. Lett.*; **13** (2003) 2167-2172.] and
20 Z-glycine according to the method described in Reference Example 1/a. MS (EI) 442.2 (M+Na⁺).

b) 4-[2-(2-Amino-acetyl-amino)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-[2-(2-benzyloxycarbonylamino-acetyl-amino)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester according to the
25 method described in Reference Example 1/b. MS (EI) 286.2 (MH⁺).

Reference Example 3

(3-[1,4']Bipiperidinyl-1'-yl)-propylamine trihydrochloride

30 **a) (3-[1,4']Bipiperidinyl-1'-yl-propyl)-carbamic acid *tert*-butyl ester**

A mixture of 4-piperidinopiperidine (Aldrich) (2.0 g, 11.88 mmol), (3-bromopropyl)-carbamic acid *tert*-butyl ester [*Eur. J. Med. Chem. Chim. Ther.* **37** (2002) 573-

584] (3.96 g, 16.63 mmol), dimethylformamide (130 mL) and potassium carbonate (1.64 g, 11.88 mmol) was stirred at room temperature overnight, then concentrated *in vacuo*. The residue was dissolved in water (150 mL), extracted with dichloromethane (3x150 mL), the combined organic layers were washed with brine (150 mL), dried over sodium sulfate, filtered and concentrated. The crude product was submitted to column chromatography using Kieselgel 60 (0.040-0.063 mm) (Merck) as adsorbent, and chloroform:methanol:ammonium hydroxide = 10:1:0.1 as eluent to yield 2.27 g (59 %) of the title compound as an oil.

10 b) 3-[1,4']Bipiperidinyl-1'-yl-propylamine trihydrochloride

A mixture of (3-[1,4']bipiperidinyl-1'-yl-propyl)-carbamic acid *tert*-butyl ester (2.15 g, 6.6 mmol), dry dioxane (40 mL) and 6.5 N hydrogen chloride in dioxane (22 mL) was stirred at room temperature overnight, then diluted with diethyl ether and stirred at 0 °C for 1 h. The precipitated crystals were filtered off, washed with diethyl ether and dried to yield 2.03 g (92 %) of the title compound as a beige solid. Mp: 305-307 °C.

Reference Example 4

Trans-4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylamine dihydrochloride

20 a) Trans-2-{1-[4-(*N*-*tert*-butoxycarbonyl)-amino]-cyclohexyl}-ethanol

A solution of trans-2-{1-[4-(*N*-*tert*-butoxycarbonyl)-amino]-cyclohexyl}-acetic acid methyl ester [*J. Med. Chem.* **43** (2000) 1878-1885] (28.5 g, 105.2 mmol) in dry tetrahydrofuran (500 mL) was cooled to -2 °C, lithium aluminum hydride (5.4 g, 142 mmol) was added portionwise and the mixture was stirred at -2 °C for 60 minutes. The reaction mixture was cooled to -10 °C and quenched with ethyl acetate (15 mL), then brine (43 mL) was slowly added to the mixture at 0 °C. The precipitated salts were filtered, and washed with ethyl acetate. The filtrate was concentrated *in vacuo*. The residue was recrystallized from diisopropyl ether (100 mL) to yield 23.7 g (93 %) of the title compound as a white powder. Mp: 100-102 °C.

30

b) Methanesulfonic acid trans-2-(4-*tert*-butoxycarbonylamino-cyclohexyl)-ethyl ester

-25 -

To a stirred solution of trans-2-{1-[4-(N-*tert*-butoxycarbonyl)-amino]-cyclohexyl}-ethanol (15 g, 62 mmol), and triethylamine (10.5 mL, 75 mmol) in dry dichloromethane (150 mL) methanesulfonyl chloride (5.7 mL, 73.4 mmol) in dichloromethane (25 mL) was added dropwise at 0 °C. After stirring 30 minutes at 0 °C, the solution was extracted three times with water. The organic solution was dried over sodium sulfate and concentrated *in vacuo* to yield 13.0 g (65 %) of the title compound. Mp: 116 °C.

c) Trans-[4-(2-pyrrolidin-1-yl-ethyl)-cyclohexyl]-carbamic acid *tert*-butyl ester

A mixture of methanesulfonic acid trans-2-(4-*tert*-butoxycarbonylamino-cyclohexyl)-ethyl ester (3.2 g, 10 mmol), potassium carbonate (1.4 g, 10 mmol) and pyrrolidine (1.25 mL, 15 mmol) in acetonitrile (40 mL) was stirred at 60 °C for 2 hours. The mixture was cooled to room temperature and poured into water (200 mL). The precipitated white crystals were filtered off and washed with water to yield 1.9 g (64 %) of the title compound. Mp: 110 °C

d) Trans-4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylamine dihydrochloride

The title compound was prepared from trans-[4-(2-pyrrolidin-1-yl-ethyl)-cyclohexyl]-carbamic acid *tert*-butyl ester according to the method described in Reference Example 3/b. Mp: 331-336 °C

Reference Example 5

4-(4-Amino-butyl)-piperidine-1-carboxylic acid *tert*-butyl ester

a) 4-(3-Methanesulfonyloxy-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester

To a solution of 4-(3-hydroxypropyl)-piperidine-1-carboxylic acid *tert*-butyl ester (2.12 g, 8.7 mmol) in dichloromethane (10 mL) triethylamine (1.33 mL, 9.57 mmol) and methanesulfonyl chloride (0.74 mL, 9.57 mmol) were added at 0 °C and the reaction mixture was stirred at this temperature for 1 h. After quenching the reaction by the addition of methanol (1 mL), the mixture was washed with water, saturated sodium hydrogencarbonate solution and water, dried over sodium sulfate, filtered and concentrated to yield 2.73 g (97%) of the title compound.

b) 4-(3-Cyano-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester

To a solution of 4-(3-methanesulfonyloxy-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester (1.35 g, 4.2 mmol) in dimethylformamide (30 mL) potassium cyanide (0.33 g, 5.1 mmol) was added and the reaction mixture was stirred at 80 °C for 20 h.
5 After concentration *in vacuo* the residue was treated with water and extracted with ethyl acetate (3x50mL). The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered and concentrated to yield 0.919 g (87%) of the title compound.

10 c) 4-(4-Amino-butyl)-piperidine-1-carboxylic acid *tert*-butyl ester

To a stirred solution of 4-(3-cyano-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester (0.896 g, 3.55 mmol) and lithium hydroxide hydrate (0.447 g, 10.65 mmol) in a mixture of dioxane (56 mL) and water (14 mL) 10% Pd/C (90 mg) and Raney Ni (0.42 g) were added. The reaction mixture was hydrogenated at 50 °C for 3 h, then the
15 catalysts were filtered off and the filtrate was concentrated. The residue was purified by column chromatography using Kieselgel 60 (0.015-0.040 mm) (Merck) as adsorbent, and methanol:ammonium hydroxide = 10:1 as eluent to yield 0.493 g (54 %) of the title compound. MS (EI) 257.2 (MH⁺).

20 Reference Example 6

4-(3-Amino-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester

a) 4-(3-Azido-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester

To a solution of 4-(3-methanesulfonyloxy-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 5/a) (1.35 g, 4.2 mmol) in dimethylformamide (30
25 mL) sodium azide (0.33 g, 5.1 mmol) was added and the reaction mixture was stirred at 80 °C for 20 h. After concentration *in vacuo* the residue was treated with water and extracted with ethyl acetate (3x50mL). The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered and concentrated to yield 1.08 g (96 %) of the title. MS (EI) 291.3 (M+Na⁺).

30

b) 4-(3-Amino-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester

-27 -

To a solution of 4-(3-azido-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester (1.738 g, 6.48 mmol) in dry tetrahydrofuran (50 mL) water (0.49 mL) and triphenyl phosphine (3.4 g, 12.96 mmol) were added. The reaction mixture was stirred at room temperature overnight, then concentrated. The residue was purified by column chromatography using Kieselgel 60 (0.015-0.040 mm) (Merck) as adsorbent, and methanol:ammonium hydroxide = 10:1 as eluent to yield 1.498 g (95 %) of the title compound. MS (EI) 243.2 (MH⁺).

Reference Example 7

N-(4-Aminomethyl-benzyl)-guanidine dihydrochloride

a) (4-(N,N'-Ditert-butoxycarbonyl-guanidinomethyl-benzyl))-carbamic acid *tert*-butyl ester

A mixture of (4-aminomethyl-benzyl)-carbamic acid *tert*-butyl ester (Aldrich) (0.47 g, 2 mmol), 1-methyl-ditert-butoxy-thiourea [*J. Org. Chem.* **52** (1987) 1700-1703] (0.6 g, 2 mmol), HgCl₂ (0.56 g, 2 mmol) and dimethylformamide (10 mL) was stirred at room temperature for 48 hours. The precipitated salts were filtered off and the filtrate was concentrated *in vacuo*. The remaining oil was dissolved in chloroform (70 mL), washed with water (3x40 mL), dried over sodium sulfate and concentrated to yield 0.65 g (68 %) of the title compound.

b) N-(4-Aminomethyl-benzyl)-guanidine dihydrochloride

The title compound was prepared from (4-(N,N'-ditert-butoxycarbonyl-guanidinomethyl-benzyl))-carbamic acid *tert*-butyl ester according to the method described in Reference Example 3/b.

Reference Example 8

2-(4-Pyridin-4-yl-piperazin-1-yl)-propylamine

a) 2-[2-(4-Pyridin-4-yl-piperazin-1-yl)-propyl]-isoindole-1,3-dione

The title compound was prepared from 1-pyridin-4-yl-piperazine [*Org. Lett.* **4** (2002) 737-740] and N-(2-bromopropyl)-phthalimide according to the method described in Reference Example 1/a.

b) 2-(4-Pyridin-4-yl-piperazin-1-yl)-propylamine

The title compound was prepared from 2-[2-(4-pyridin-4-yl-piperazin-1-yl)-propyl]-isoindole-1,3-dione according to the method described in Reference Example 1/b.

5

Example 1

4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

a) 2,4-Dichloro-1-(2-nitro-phenoxy)-benzene

10 A mixture of 1-fluoro-2-nitrobenzene (4.8 mL, 45.42 mmol), potassium carbonate (13.8 g, 0.1 mol) and 2,4-dichloro-phenol (8.16 g, 50.06 mmol) in dry dimethylformamide (70 mL) was stirred at 100 °C for 2 h. Solids were filtered off, and the filtrate was concentrated in vacuo. The residue was partitioned between diethyl ether and 1N sodium hydroxide, the organic layer was washed with 1N sodium hydroxide,
15 water and brine, dried over sodium sulfate, filtered and concentrated *in vacuo* to yield 11.69 g (91 %) of the title compound as a yellowish oil, which solidifies on standing. Mp: 58-59 °C. MS (EI) 285.2 (MH⁺). Lit. [*Chem. Heterocycl. Compd. (Engl. Transl.)* 11 (1975) 1356-1358] Mp: 57-58 °C.

20 b) 2-(2,4-Dichloro-phenoxy)-phenylamine [*Chem. Abstr.* 84 (1976) 164313q]

To a stirred solution of 2,4-dichloro-1-(2-nitro-phenoxy)-benzene (3.5 g, 12.32 mmol) in ethyl acetate (60 mL) stannous chloride dihydrate (13.89 g, 61.6 mmol) was added and the mixture was refluxed for 2 h before it was quenched with saturated sodium hydrogencarbonate solution (192 mL). The organic phase was separated and the
25 aqueous phase was washed several times with ethyl acetate. The combined extracts were dried over sodium sulfate, filtered and concentrated in vacuo to yield 3.1 g (99 %) of the title compound as a yellowish oil: MS (EI) 255.2 (MH⁺).

c) 4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoic acid

30 Under an atmosphere of argon to an ice cooled solution of 2-(2,4-dichloro-phenoxy)-phenylamine (0.5 g, 1.97 mmol) in dry pyridine (5 mL) 4-chlorosulfonyl benzoic acid (0.45 g, 1.97 mmol) was added portion-wise. The reaction mixture was

stirred at room temperature overnight. The mixture was evaporated *in vacuo*, the residue was treated with 1N hydrochloric acid (20 mL), and extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with 1N hydrochloric acid, water and brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. The residue was submitted to flash column chromatography using Kieselgel 60 (0.015-0.040 mm) as adsorbent (Merck) and chloroform:methanol:acetic acid = 294:6:1 as eluent to yield 0.6 g (70 %) of the title compound as a light pink solid, which was crystallized from diethyl ether-petroleum ether. MS (EI) 439.3 (MH⁺).

10 d) 4-[(2-{4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The solution of 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoic acid (3.07 g, 7.0 mmol), triethylamine (1.0 mL, 7.1 mmol) and HBTU [O-benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (Advanced Chem. Tech.)] (3.21 g, 8.45 mmol) in dry dimethylformamide (100 mL) was stirred at room temperature for five minutes before 4-[(2-amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) (1.9 g, 7.0 mmol) was added. The pH of the reaction mixture was adjusted to 8 by the addition of triethylamine, the so obtained mixture was stirred at room temperature overnight, then concentrated *in vacuo*. The residue was treated with saturated sodium hydrogencarbonate solution (100 mL), extracted with ethyl acetate (3x100 mL), the combined organic layers were washed with saturated sodium hydrogencarbonate solution, water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography using Kieselgel 60 (0.040-0.063 mm) as adsorbent (Merck) and toluene:acetone = 2:1 as eluent to yield 2.86 g (59 %) of the title compound as light yellowish amorphous solid. MS (EI) 714 (M+Na⁺).

30 e) 4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

To a stirred solution of 4-(2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (1.07 g, 1.55 mmol) in dichloromethane (11 mL) 9 M hydrogen chloride in ethanol (0.91 mL)

-30 -

was added. The reaction mixture was stirred at room temperature for 2h, then diethyl ether (36 mL) was added, the precipitated crystals were filtered, washed with diethyl ether and dried to yield 0.655 g (67 %) of the title compound. MS (EI) 592.1 (MH⁺).

5 **Example 2**

4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(3-piperidin-1-yl-propylcarbamoyl)-methyl]-benzamide

a) {4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid ethyl ester

10 The solution of 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoic acid (Example 1/c) (8.207 g, 18.7 mmol), triethylamine (5.2 mL, 37.4 mmol) and HBTU (8.24 g, 21.7 mmol) in dry dimethyl formamide (150 mL) was stirred at room temperature for five minutes before glycine ethyl ester hydrochloride (Aldrich) (2.614 g, 18.7 mmol) was added. The pH of the reaction mixture was adjusted to 8 by the
15 addition of triethylamine, the so obtained mixture was stirred at room temperature overnight, then concentrated *in vacuo*. The residue was treated with saturated sodium hydrogencarbonate solution (300 mL), the precipitated crystals were filtered off, washed with water and dried. The crude product was purified by column chromatography using Kieselgel 60 (0.040-0.063 mm) (Merck) as adsorbent, and n-hexane:ethyl acetate = 2:1
20 as eluent to yield 7.68 g (78 %) of the title compound. MS (EI) 524 (MH⁺).

b) {4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid

To a stirred solution of {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid ethyl ester (7.68 g, 14.67 mmol) in a mixture of
25 tetrahydrofuran (36 mL), water (18 mL) and methanol (18 mL) lithium hydroxide monohydrate (3.09 g, 73.64 mmol) was added and the reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated, the residue was dissolved in water, acidified with 1M hydrochloric acid, the precipitated solid was filtered off, washed with water and dried to yield 6.76 g (93 %) of the title compound as a yellowish
30 solid. MS (EI) 496.2 (MH⁺).

c) 4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(3-piperidin-1-yl-propylcarbamoyl)-methyl]-benzamide

To a stirred solution of {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (42 mg, 0.085 mmol) in a mixture of dichloromethane (2 mL) and dimethylformamide (0.2 mL) 3-piperidin-1-yl-propylamine (EMKA-Chemie) (14 mg, 0.1 mmol), HBTU (46 mg, 0.12 mmol) and triethylamine (60 μ L, 0.4 mmol) were added. The mixture was stirred at room temperature for 24 h, then purified by column chromatography using Kieselgel 60 (0.015-0.040 mm) as adsorbent (Merck) and gradient elution starting with 100% A eluent and processing to a mixture of 70% A and 30% B eluent over a period of 15 minutes (eluent A: chloroform; eluent B: methanol containing 5% of ammonium hydroxide) to yield 50.2 mg (95 %) of the title compound. MS (EI) 620.2 (MH^+).

Example 3

15 4-[2-(4-Bromo-phenoxy)-phenylsulfamoyl]-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl]-benzamide trifluoroacetate

a) 4-[2-(4-Bromo-phenoxy)-phenylsulfamoyl]-benzoic acid

To a stirred solution of 2-(4-bromo-phenoxy)-phenylamine [*J. Chem.. Soc.* (1930) 1202, 1206] (1.708 g, 6.5 mmol) in dry pyridine (10 mL) 4-chlorosulfonyl benzoic acid (1.66 g, 7.5 mmol) was added. The reaction mixture was stirred at room temperature overnight, then poured into ice-water (100 mL). The precipitated crystals were filtered off, washed with water and dried to yield 2.37 g (81 %) of the title compound. MS (EI) 449.2 (MH^+).

25 b) 4-[(2-{4-[2-(4-Bromo-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-[2-(4-bromo-phenoxy)-phenylsulfamoyl]-benzoic acid and 4-[(2-amino-acetylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method described in Example 1/d. MS (EI) 724.2 ($M+Na^+$).

c) 4-[2-(4-Bromo-phenoxy)-phenylsulfamoyl]-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide trifluoroacetate

To an ice cold solution of 4-[(2-{4-[2-(4-bromo-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (0.80 g, 1.14 mmol) in dichloromethane (40 mL) trifluoroacetic acid (10 mL) was added and the reaction mixture was stirred at room temperature overnight, then concentrated. The residue was triturated with diethyl ether, filtered and dried to yield 0.748 g (82 %) of the title compound as a white amorphous solid. MS (EI) 602.1 (MH⁺).

10 **Example 4**

4-[2-(4-Bromo-phenoxy)-5-fluoro-phenylsulfamoyl]-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide trifluoroacetate

a) 4-[2-(4-Bromo-phenoxy)-5-fluoro-phenylsulfamoyl]-benzoic acid

Under an atmosphere of argon to an ice cooled solution of 2-(4-bromo-phenoxy)-5-fluoro-phenylamine [*Yakugaku Zasshi*; **87** (1967) 591, 594; *Chem. Abstr.*; **67** (1967) 73282] (0.43 g, 1.52 mmol) in dry pyridine (10 mL) 4-chlorosulfonyl benzoic acid (0.34 g, 1.52 mmol) was added portion-wise. The reaction mixture was stirred at room temperature overnight. The mixture was concentrated *in vacuo*, the residue was treated with 1N hydrochloric acid (15 mL), and extracted with ethyl acetate (3x20 mL). The combined organic layers were washed with 1N hydrochloric acid, water and brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. The residue was triturated with diethyl ether, filtered, washed with diethyl ether and dried to yield 0.31 g (43 %) of the title compound as a light pink solid. MS (EI) 467.9 (MH⁺).

b) {4-[2-(4-Bromo-phenoxy)-5-fluoro-phenylsulfamoyl]-benzoylamino}-acetic acid ethyl ester

The title compound was prepared from 4-[2-(4-bromo-phenoxy)-5-fluoro-phenylsulfamoyl]-benzoic acid and glycine ethyl ester hydrochloride (Aldrich) according to the method described in Example 1/d. MS (EI) 552.0 (MH⁺).

c) {4-[2-(4-Bromo-phenoxy)-5-fluoro-phenylsulfamoyl]-benzoylamino}-acetic acid

The title compound was prepared from {4-[2-(4-bromo-phenoxy)-5-fluoro-phenylsulfamoyl]-benzoylamino}-acetic acid ethyl ester according to the method described in Example 2/b. MS (EI) 524.2 (MH^+).

- 5 d) 4-[(2-{4-[2-(4-Bromo-phenoxy)-5-fluoro-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from {4-[2-(4-bromo-phenoxy)-5-fluoro-phenylsulfamoyl]-benzoylamino}-acetic acid and 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester (Fluka) according to the method described in Example
10 1/d. MS (EI) 743.3 ($M+Na^+$).

- e) 4-[2-(4-Bromo-phenoxy)-5-fluoro-phenylsulfamoyl]-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide mono trifluoroacetate

The title compound was prepared from 4-[(2-{4-[2-(4-bromo-phenoxy)-5-fluoro-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-methyl]-piperidine-1-carboxylic acid
15 *tert*-butyl ester according to the method described in Example 3/c. MS (EI) 620.2 (MH^+).

Example 5

- 20 **4-(2-Phenoxy-phenylsulfamoyl)-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride**

- a) 4-(2-Phenoxy-phenylsulfamoyl)-benzoic acid

The title compound was prepared from 2-phenoxy-phenylamine (Aldrich) according to the method described in Example 3/a. MS (EI) 370.2 (MH^+).

25

- b) 4-({2-[4-(2-Phenoxy-phenylsulfamoyl)-benzoylamino]-acetyl-amino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic acid and 4-[(2-amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester
30 (Reference Example 1) according to the method described in Example 1/d. MS (EI) 645.2 ($M+Na^+$).

c) 4-(2-Phenoxy-phenylsulfamoyl)-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

The title compound was prepared from 4-({2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetylamino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 523.2 (MH⁺).

Example 6

4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-{2-phenyl-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl}-benzamide hydrochloride

a) 2-{4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-3-phenyl-propionic acid methyl ester

The title compound was prepared from 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoic acid (Example 1/c) and (DL)-phenylalanine methyl ester hydrochloride according to the method described in Example 1/d. MS (EI) 600.2 (MH⁺).

b) 2-{4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-3-phenyl-propionic acid

The title compound was prepared from 2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-3-phenyl-propionic acid methyl ester according to the method described in Example 2/b. MS (EI) 586.2 (MH⁺).

c) 4-[(2-{4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-3-phenyl-propionylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-3-phenyl-propionic acid and 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/d. MS (EI) 804.1 (M+Na⁺).

d) 4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-{2-phenyl-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl}-benzamide hydrochloride

The title compound was prepared from 4-[(2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-3-phenyl-propionylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 682.2 (MH⁺).

5

Example 7**4-(5-Fluoro-2-phenoxy-phenylsulfamoyl)-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride****a) 4-(5-Fluoro-2-phenoxy-phenylsulfamoyl)-benzoic acid**

10 The title compound was prepared from 5-fluoro-2-phenoxy-phenylamine [*Bioorg. Med. Chem.*; **12** (2004) 423-438] according to the method described in Example 1/c. MS (EI) 388.2 (MH⁺).

15 **b) 4-({2-[4-(5-Fluoro-2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetyl-amino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester**

The title compound was prepared from 4-(5-fluoro-2-phenoxy-phenylsulfamoyl)-benzoic acid and 4-[(2-amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method described in Example 1/d. MS (EI) 641.2 (MH⁺).

20

c) 4-(5-Fluoro-2-phenoxy-phenylsulfamoyl)-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

The title compound was prepared from 4-({2-[4-(5-fluoro-2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetyl-amino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 541.2 (MH⁺).

25

Example 8**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-{(S)-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl}-benzamide hydrochloride**

30

a) (S)-2-{4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-propionic acid benzyl ester

The title compound was prepared from 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoic acid (Example 1/c) and (*S*)-2-amino-propionic acid benzyl ester according to the method described in Example 1/d. MS (EI) 600.2 (MH⁺).

5 b) (*S*)-2-{4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-propionic acid

The title compound was prepared from (*S*)-2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-propionic acid benzyl ester according to the method described in Example 2/b. MS (EI) 510.1 (MH⁺).

10 c) 4-[(*S*)-2-{4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-propionylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from (*S*)-2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-propionic acid and 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/d. MS
15 (EI) 706.1 (MH⁺).

d) 4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-*N*-{(S)-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl}-benzamide hydrochloride

The title compound was prepared from 4-[(*S*)-2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-propionylamino)-methyl]-piperidine-1-carboxylic
20 acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 606.1 (MH⁺).

Example 9

25 4-(Biphenyl-2-ylsulfamoyl)-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

a) 4-(Biphenyl-2-ylsulfamoyl)-benzoic acid

The title compound was prepared from 2-amino-biphenyl (Aldrich) according to the method described in Example 1/c. MS (EI) 354.1 (MH⁺).

30

b) 4-({2-[4-(Biphenyl-2-ylsulfamoyl)-benzoylamino]-acetyl-amino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-(biphenyl-2-ylsulfamoyl)-benzoic acid and 4-[(2-amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method described in Example 1/d. MS (EI) 629.2 (M+Na⁺).

5

c) 4-(Biphenyl-2-ylsulfamoyl)-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

The title compound was prepared from 4-({2-[4-(biphenyl-2-ylsulfamoyl)-benzoylamino]-acetyl-amino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 507.2 (MH⁺).

10

Example 10

4-(2-Phenoxy-phenylsulfamoyl)-N-[(2-piperidin-4-yl-ethylcarbamoyl)-methyl]-benzamide hydrochloride

a) 4-(2-{2-[4-(2-Phenoxy-phenylsulfamoyl)-benzoylamino]-acetyl-amino}-ethyl)-piperidine-1-carboxylic acid *tert*-butyl ester

15

The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic acid (Example 5/a) and 4-[2-(2-amino-acetyl-amino)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 2) according to the method described in Example 1/d. MS (EI) 659.2 (M+Na⁺).

20

b) 4-(2-Phenoxy-phenylsulfamoyl)-N-[(2-piperidin-4-yl-ethylcarbamoyl)-methyl]-benzamide hydrochloride

The title compound was prepared from 4-({2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetyl-amino}-ethyl)-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 537.2 (MH⁺).

25

Example 11

4-[2-(2,4-Dichloro-phenoxy)-4-methoxy-phenylsulfamoyl]-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

30

a) 2,4-Dichloro-1-(5-methoxy-2-nitro-phenoxy)-benzene

The title compound was prepared from 2-fluoro-4-methoxy-1-nitro-benzene [*J. Med. Chem.*; **33** (1990) 286-291] and 2,4-dichloro-phenol according to the method described in Example 1/a. MS (EI) 315.1 (MH⁺).

5 b) 2-(2,4-Dichloro-phenoxy)-4-methoxy-phenylamine

The title compound was prepared from 2,4-dichloro-1-(5-methoxy-2-nitro-phenoxy)-benzene according to the method described in Example 1/b. MS (EI) 285.2 (MH⁺).

10 c) 4-[2-(2,4-Dichloro-phenoxy)-4-methoxy-phenylsulfamoyl]-benzoic acid

The title compound was prepared from 2-(2,4-dichloro-phenoxy)-4-methoxy-phenylamine according to the method described in Example 1/c. MS (EI) 469.1 (MH⁺).

15 d) 4-[(2-{4-[2-(2,4-Dichloro-phenoxy)-4-methoxy-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-[2-(2,4-dichloro-phenoxy)-4-methoxy-phenylsulfamoyl]-benzoic acid and 4-[(2-amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method described in Example 1/d. MS (EI) 744.2 (M+Na⁺).

20

e) 4-[2-(2,4-Dichloro-phenoxy)-4-methoxy-phenylsulfamoyl]-N-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

The title compound was prepared from 4-[(2-{4-[2-(2,4-dichloro-phenoxy)-4-methoxy-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 622.2 (MH⁺).

Example 12

30 4-[2-(4-Fluoro-phenoxy)-phenylsulfamoyl]-N-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

a) 4-[2-(4-Fluoro-phenoxy)-phenylsulfamoyl]-benzoic acid

The title compound was prepared from 2-(4-fluoro-phenoxy)-phenylamine [*Helv. Chim. Acta*; **48** (1965) 336-347] according to the method described in Example 1/c. MS (EI) 388.2 (MH⁺).

5 b) 4-[(2-{4-[2-(4-Fluoro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-[2-(4-fluoro-phenoxy)-phenylsulfamoyl]-benzoic acid and 4-[(2-amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method
10 described in Example 1/d. MS (EI) 663.2 (M+Na⁺).

c) 4-[2-(4-Fluoro-phenoxy)-phenylsulfamoyl]-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl]-benzamide hydrochloride

The title compound was prepared from 4-[(2-{4-[2-(4-fluoro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-methyl]-piperidine-1-carboxylic acid
15 *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 541.2 (MH⁺).

Example 13

20 **4-[5-Fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-N-[(2-piperidin-4-yl-ethylcarbamoyl)-methyl]-benzamide hydrochloride**

a) 4-[5-Fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-benzoic acid

The title compound was prepared from 5-fluoro-2-(4-fluoro-phenoxy)-phenylamine [*Yakugaku Zasshi*; **88** (1968) 1361, 1365; *Chem. Abstr.*; **70** (1969) 68312]
25 according to the method described in Example 1/c. MS (EI) 406.3 (MH⁺).

b) 4-[2-(2-{4-[5-Fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-[5-fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-benzoic acid and 4-[2-(2-amino-acetyl-amino)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 2) according to the method
30 described in Example 1/d. MS (EI) 695.2 (M+Na⁺).

c) 4-[5-Fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-N-[(2-piperidin-4-yl-ethylcarbamoyl)-methyl]-benzamide hydrochloride

The title compound was prepared from 4-[2-(2-{4-[5-fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetylamino)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 573.2 (MH⁺).

Example 14

10 N-{[(1-Carbamimidoyl-piperidin-4-ylmethyl)-carbamoyl]-methyl}-4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzamide hydrochloride

a) (*tert*-Butoxycarbonylimino-{4-[(2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetylamino)-methyl]-piperidin-1-yl}-methyl)-carbamic acid *tert*-butyl ester

15 To a stirred solution of 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-N-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride (Example 1/e) (176 mg, 0.28 mmol) in dimethylformamide (3 mL) *N,N'*-bis(*tert*-butoxycarbonyl)-1*H*-pyrazole-1-carboxamidine (Aldrich) (160 mg, 0.5 mmol) and *N,N*-diisopropylethylamine (52 µL, 0.3 mmol) were added. After stirring at room
20 temperature for 4 days the reaction mixture was concentrated and the residue was submitted to column chromatography using Kieselgel 60 (0.040-0.063 mm) (Merck) as adsorbent, and ethyl acetate:n-hexane = 5:1 as eluent to yield 150 mg (64 %) of the title compound.

25 b) N-{[(1-Carbamimidoyl-piperidin-4-ylmethyl)-carbamoyl]-methyl}-4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzamide hydrochloride

To a stirred solution of (*tert*-butoxycarbonylimino-{4-[(2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetylamino)-methyl]-piperidin-1-yl}-methyl)-carbamic acid *tert*-butyl ester (140 mg, 0.17 mmol) in ethyl acetate (0.5 mL)
30 2.5 M hydrogen chloride in ethyl acetate (3.0 mL) was added and the mixture was stirred at room temperature for 24 h. The precipitated product was filtered, washed with

diethyl ether and dried in vacuum to yield 110 mg (98 %) of the title compound. MS (EI) 634.1 (MH^+).

Example 15

5 **4-[5-Fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride**

a) 4-[2-(2-{4-[5-Fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

10 The title compound was prepared from 4-[5-fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-benzoic acid and 4-[2-(2-amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method described in Example 1/d. MS (EI) 681.3 ($M+Na^+$).

15 b) 4-[5-Fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-N-[(2-piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

The title compound was prepared from 4-[(2-{4-[5-fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 559.4 (MH^+).

20

Example 16

N-[(2-Oxo-2-piperazin-1-yl-ethylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide hydrochloride

a) 4-(2-Benzoyloxycarbonylamino-acetyl)-piperazine-1-carboxylic acid *tert*-butyl ester

25 The title compound was prepared from Z-glycine and piperazine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/d. MS (EI) 400.2 ($M+Na^+$).

b) 4-(2-Amino-acetyl)-piperazine-1-carboxylic acid *tert*-butyl ester acetate

30 The title compound was prepared from 4-(2-benzoyloxycarbonylamino-acetyl)-piperazine-1-carboxylic acid *tert*-butyl ester according to the method described in Reference Example 1/b. MS (EI) 244.2 (MH^+).

c) 4-[2-(2-Benzylloxycarbonylamino-acetyl)-piperazine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from Z-glycine and 4-(2-amino-acetyl)-
5 piperazine-1-carboxylic acid *tert*-butyl ester according to the method described in
Example 1/d. MS (EI) 457.1 (M+Na⁺).

d) 4-[2-(2-Amino-acetyl)-piperazine-1-carboxylic acid *tert*-butyl ester
acetate

10 The title compound was prepared from 4-[2-(2-benzylloxycarbonylamino-
acetyl)-piperazine-1-carboxylic acid *tert*-butyl ester according to the
method described in Reference Example 1/b. MS (EI) 301.2 (MH⁺).

e) 4-(2-{2-[4-(2-Phenoxy-phenylsulfamoyl)-benzoylamino]-acetyl}-
15 piperazine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic
acid (Example 5/a) and 4-[2-(2-amino-acetyl)-piperazine-1-carboxylic
acid *tert*-butyl ester acetate according to the method described in Example 1/d. MS (EI)
674.4 (M+Na⁺).

20 f) N-[(2-Oxo-2-piperazin-1-yl-ethyl)carbamoyl]-methyl-4-(2-phenoxy-
phenylsulfamoyl)-benzamide hydrochloride

The title compound was prepared from 4-(2-{2-[4-(2-phenoxy-
phenylsulfamoyl)-benzoylamino]-acetyl}-piperazine-1-carboxylic acid
25 *tert*-butyl ester according to the method described in Example 1/e followed by
preparative HPLC purification. MS (EI) 552.2 (MH⁺).

Example 17

**4-(2-Benzyl-phenylsulfamoyl)-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-
30 benzamide hydrochloride**

a) 4-(2-Benzyl-phenylsulfamoyl)-benzoic acid

-43 -

The title compound was prepared from 2-benzyl-aniline (Aldrich) according to the method described in Example 1/c. MS (EI) 368.2 (MH^+).

b) 4-({2-[4-(2-Benzyl-phenylsulfamoyl)-benzoylamino]-acetylamino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-(2-benzyl-phenylsulfamoyl)-benzoic acid and 4-[(2-amino-acetylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method described in Example 1/d. MS (EI) 643.2 ($M+Na^+$).

c) 4-(2-Benzyl-phenylsulfamoyl)-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

The title compound was prepared from 4-({2-[4-(2-benzyl-phenylsulfamoyl)-benzoylamino]-acetylamino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 521.5 (MH^+).

Example 18

4-(2-Benzoyl-phenylsulfamoyl)-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

a) 4-(2-Benzoyl-phenylsulfamoyl)-benzoic acid

The title compound was prepared from 2-aminobenzophenone (Aldrich) according to the method described in Example 1/c. MS (EI) 382.2 (MH^+).

b) 4-({2-[4-(2-Benzoyl-phenylsulfamoyl)-benzoylamino]-acetylamino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-(2-benzoyl-phenylsulfamoyl)-benzoic acid and 4-[(2-amino-acetylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method described in Example 1/d. MS (EI) 657.2 ($M+Na^+$).

c) 4-(2-Benzoyl-phenylsulfamoyl)-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

The title compound was prepared from 4-({2-[4-(2-benzoyl-phenylsulfamoyl)-benzoylamino]-acetylamino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 535.2 (MH^+).

5 **Example 19**

N-Methyl-4-(2-phenoxy-phenylsulfamoyl)-N-[[piperidin-4-ylmethyl]-carbamoyl]-methyl}-benzamide trifluoroacetate

a) {Methyl-[4-(2-phenoxy-phenylsulfamoyl)-benzoyl]-amino}-acetic acid methyl ester

The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic acid (Example 5/a) and sarcosine methyl ester hydrochloride (Aldrich) according to the method described in Example 1/d. MS (EI) 455.2 (MH^+).

b) {Methyl-[4-(2-phenoxy-phenylsulfamoyl)-benzoyl]-amino}-acetic acid

The title compound was prepared from {methyl-[4-(2-phenoxy-phenylsulfamoyl)-benzoyl]-amino}-acetic acid methyl ester according to the method described in Example 2/b. MS (EI) 441.2 (MH^+).

c) 4-[(2-{Methyl-[4-(2-phenoxy-phenylsulfamoyl)-benzoyl]-amino}-acetylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from {methyl-[4-(2-phenoxy-phenylsulfamoyl)-benzoyl]-amino}-acetic acid and 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/d. MS (EI) 659.2 ($M+Na^+$).

d) N-Methyl-4-(2-phenoxy-phenylsulfamoyl)-N-[[piperidin-4-ylmethyl]-carbamoyl]-methyl}-benzamide trifluoroacetate

The title compound was prepared from 4-[(2-{methyl-[4-(2-phenoxy-phenylsulfamoyl)-benzoyl]-amino}-acetylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 3/c. MS (EI) 537.2 (MH^+).

Example 20

N-{1-Methyl-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl}-4-(2-phenoxy-phenylsulfamoyl)-benzamide hydrochloride

a) 2-Methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid methyl ester

5 The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic acid (Example 5/a) and α -amino-isobutyric acid methyl ester hydrochloride [*Collect. Czech. Chem. Commun.*; **63** (1998) 85-93] according to the method described in Example 1/d. MS (EI) 469.1 (MH^+).

10 b) 2-Methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid

 The title compound was prepared from 2-methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid methyl ester according to the method described in Example 2/b. MS (EI) 455.1 (MH^+).

15 c) 4-({2-Methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionylamino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester

 The title compound was prepared from 2-methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid and 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/d. MS
20 (EI) 673.4 ($M+Na^+$).

d) N-{1-Methyl-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl}-4-(2-phenoxy-phenylsulfamoyl)-benzamide hydrochloride

 The title compound was prepared from 4-({2-methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionylamino}-methyl)-piperidine-1-carboxylic
25 acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 551.2 (MH^+).

Example 21

30 **N-{(S)-2-Methyl-1-[(piperidin-4-ylmethyl)-carbamoyl]-propyl}-4-(2-phenoxy-phenylsulfamoyl)-benzamide trifluoroacetate**

a) (S)-3-Methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyric acid *tert*-butyl ester

The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic acid (Example 5/a) and L-valine *tert*-butyl ester hydrochloride (Aldrich) according to the method described in Example 1/d. MS (EI) 547.2 (M+Na⁺).

b) (S)-3-Methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyric acid

To a solution of (S)-3-methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyric acid *tert*-butyl ester (0.56 g, 1.07 mmol) in dichloromethane (25 mL) trifluoroacetic acid (6.5 mL) was added and the reaction mixture was stirred at room temperature for 4 h, then concentrated to yield 0.467 g (93 %) of the title. MS (EI) 469.2 (MH⁺).

c) 4-({(S)-3-Methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyrylamino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from (S)-3-methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyric acid and 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/d. MS (EI) 687.2 (M+Na⁺).

d) N-{{(S)-2-Methyl-1-[(piperidin-4-ylmethyl)-carbamoyl]-propyl}-4-(2-phenoxy-phenylsulfamoyl)-benzamide trifluoroacetate

The title compound was prepared from 4-({(S)-3-methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyrylamino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 3/c. MS (EI) 565.2 (MH⁺).

Example 22

4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(2-piperidin-4-yl-ethylcarbamoyl)-methyl]-benzamide acetate

a) 4-[2-(2-{4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoic acid (Example 1/c) and 4-[2-(2-amino-acetyl-amino)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 2) according to the method described in Example 1/d. MS (EI) 728.2 (M+Na⁺).

5

b) 4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(2-piperidin-4-yl-ethylcarbamoyl)-methyl]-benzamide acetate

The title compound was prepared from 4-[2-(2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-ethyl]-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e followed by preparative HPLC purification. MS (EI) 606.2 (MH⁺).

10

Example 23

4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(2-piperidin-1-yl-ethylcarbamoyl)-methyl]-benzamide

15

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 2-piperidin-1-yl-ethylamine (EMKA-Chemie) according to the method described in Example 2/c. MS (EI) 606.2 (MH⁺).

20

Example 24

4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(2-dimethylamino-ethyl)-methyl-carbamoyl]-methyl]-benzamide

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and *N,N,N*-trimethylethylenediamine (Aldrich) according to the method described in Example 2/c. MS (EI) 580.2 (MH⁺).

25

Example 25

4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(3-dimethylamino-propylcarbamoyl)-methyl]-benzamide

30

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 3-dimethylamino-1-propylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 580.2 (MH⁺).

5

Example 26**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(3-diethylamino-propylcarbamoyl)-methyl]-benzamide**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 3-diethylamino-1-propylamine (Fluka) according to the method described in Example 2/c. MS (EI) 608.2 (MH⁺).

10

Example 27

15 **4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(3-morpholin-4-yl-propylcarbamoyl)-methyl]-benzamide**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 3-morpholin-4-yl propylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 622.2 (MH⁺).

20

Example 28**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-{[3-(2-methyl-piperidin-1-yl)-propylcarbamoyl]-methyl}-benzamide**

25 The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 3-(2-methyl-piperidin-1-yl)-propylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 634.2 (MH⁺).

25

30 **Example 29**

4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(3-imidazol-1-yl-propylcarbamoyl)-methyl]-benzamide

30

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 3-imidazol-1-yl-propylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 603.2 (MH⁺).

5

Example 30**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(2-morpholin-4-yl-ethylcarbamoyl)-methyl]-benzamide**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 2-morpholin-4-yl-ethylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 608.2 (MH⁺).

10

Example 31**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(2-pyrrolidin-1-yl-ethylcarbamoyl)-methyl]-benzamide**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 2-pyrrolidin-1-yl-ethylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 592.2 (MH⁺).

20

Example 32**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(2-diisopropylamino-ethylcarbamoyl)-methyl]-benzamide**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 2-diisopropylamino-1-ethylamine (Fluka) according to the method described in Example 2/c. MS (EI) 622.2 (MH⁺).

25

Example 33**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(2-dimethylamino-1-methyl-ethylcarbamoyl)-methyl]-benzamide**

30

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 2-dimethylamino-1-methyl-ethylamine (Fluka) according to the method described in Example 2/c. MS (EI) 580.2 (MH^+).

5

Example 34

4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(2-methylamino-ethylcarbamoyl)-methyl]-benzamide hydrochloride

To a stirred solution of {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) (42 mg, 0.085 mmol) in a mixture of
10 dichloromethane (2 mL) and dimethylformamide (0.2 mL) and (2-amino-ethyl)-methylcarbamic acid *tert*-butyl ester (Fluka) (17 mg, 0.1 mmol), HBTU (46 mg, 0.12 mmol) and triethylamine (30 μ L, 0.2 mmol) were added. The mixture was stirred at room temperature for 24 h, then purified by column chromatography using Kieselgel 60
15 (0.015-0.040 mm) as adsorbent (Merck) and gradient elution starting with 100% A eluent and processing to 100% B eluent over a period of 20 minutes (eluent A: n-hexane; eluent B: ethyl acetate). The purified compound was dissolved in ethyl acetate (0.5 mL) 2.5 M hydrogen chloride in ethyl acetate (2.0 mL) was added and the mixture was stirred at room temperature for 24 h. The precipitated product was filtered, washed
20 with diethyl ether and dried in vacuum to yield 31 mg (62 %) of the title compound. MS (EI) 552.2 (MH^+).

Example 35

4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(3-dimethylamino-2,2-dimethyl-propylcarbamoyl)-methyl]-benzamide

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and N,N,2,2-tetramethyl-1,3-propanediamine (Aldrich) according to the method described in Example 2/c. MS
30 (EI) 608.2 (MH^+).

Example 36

4-[2-(3-Diethylamino-phenoxy)-phenylsulfamoyl]-N-[[piperidin-4-ylmethyl]-carbamoyl]-methyl}-benzamide hydrochloride

a) 3-Diethylamino-1-(2-nitro-phenoxy)-benzene

The title compound was prepared from 3-diethylamino-phenol according to the method described in Example 1/a. MS (EI) 287.1 (MH⁺).

b) 2-(3-Diethylamino-phenoxy)-phenylamine

The title compound was prepared from 3-diethylamino-1-(2-nitro-phenoxy)-benzene according to the method described in Example 1/b.

c) 4-[2-(3-Diethylamino-phenoxy)-phenylsulfamoyl]-benzoic acid

The title compound was prepared from 2-(3-diethylamino-phenoxy)-phenylamine according to the method described in Example 1/c. MS (EI) 441.1 (MH⁺).

d) 4-[2-(3-Diethylamino-phenoxy)-phenylsulfamoyl]-N-[[piperidin-4-ylmethyl]-carbamoyl]-methyl}-benzamide hydrochloride

The title compound was prepared from 4-[2-(3-diethylamino-phenoxy)-phenylsulfamoyl]-benzoic acid and 4-[(2-amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method described in Example 34. MS (EI) 594.3 (MH⁺).

Example 37

4-[2-(4-Bromo-2-chloro-phenoxy)-phenylsulfamoyl]-N-[[piperidin-4-ylmethyl]-carbamoyl]-methyl}-benzamide hydrochloride

a) 4-Bromo-2-chloro-1-(2-nitro-phenoxy)-benzene

The title compound was prepared from 4-bromo-2-chloro-phenol according to the method described in Example 1/a. MS (EI) 329.3 (MH⁺).

b) 2-(4-Bromo-2-chloro-phenoxy)-phenylamine

The title compound was prepared from 4-bromo-2-chloro-1-(2-nitro-phenoxy)-benzene according to the method described in Example 1/b. MS (EI) 300.2 (MH⁺).

c) 4-[2-(4-Bromo-2-chloro-phenoxy)-phenylsulfamoyl]-benzoic acid

The title compound was prepared from 2-(4-bromo-2-chloro-phenoxy)-phenylamine according to the method described in Example 1/c.

5 d) 4-[2-(4-Bromo-2-chloro-phenoxy)-phenylsulfamoyl]-N-[[piperidin-4-ylmethyl]-carbamoyl]-methyl}-benzamide hydrochloride

The title compound was prepared from 4-[2-(4-bromo-2-chloro-phenoxy)-phenylsulfamoyl]-benzoic acid and 4-[(2-amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 12 according to the method
10 described in Example 34. MS (EI) 637.1 (MH⁺).

Example 38

Dimethyl-carbamic acid 4-[2-(2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-ethyl]-phenyl ester

15 The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and dimethyl-carbamic acid 4-(2-amino-ethyl)-phenyl ester [WO2003093245] according to the method described in Example 2/c. MS (EI) 686.2 (MH⁺).

20

Example 39

4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(4-guanidinomethyl)-benzylcarbamoyl]-methyl}-benzamide hydrochloride

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and *N*-(4-aminomethyl-benzyl)-guanidine dihydrochloride (Reference Example 7) according to the method
25 described in Example 2/c. MS (EI) 656.2 (MH⁺).

Example 40

30 **4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[[methyl-(2-pyridin-2-yl-ethyl)-carbamoyl]-methyl}-benzamide**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and methyl-(2-pyridin-2-yl-ethyl)-amine (Aldrich) according to the method described in Example 2/c. MS (EI) 614.3 (MH⁺).

5

Example 41**N-{[Bis-(3-dimethylamino-propyl)-carbamoyl]-methyl}-4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzamide**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and N-(3-dimethylamino-propyl)-N',N'-dimethylpropane-1,3-diamine (Aldrich) according to the method described in Example 2/c. MS (EI) 665.2 (MH⁺).

Example 42**2-(2-{4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-(S)-3-(1H-imidazol-4-yl)-propionic acid methyl ester**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and L-histidine methyl ester dihydrochloride (Aldrich) according to the method described in Example 2/c. MS (EI) 647.2 (MH⁺).

20

Example 43**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-{[methyl-(2-pyridin-4-yl-ethyl)-carbamoyl]-methyl}-benzamide**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and methyl-(2-pyridine-4-yl-ethyl)-amine (Aldrich) according to the method described in Example 2/c. MS (EI) 614.2 (MH⁺).

25

Example 44**2-(2-{4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetyl-amino)-(S)-5-guanidino-pentanoic acid methyl ester hydrochloride**

30

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and L-arginine methyl ester dihydrochloride (Fluka) according to the method described in Example 2/c. MS (EI) 666.2 (MH⁺).

5

Example 45**(S)-2-Amino-6-(2-{4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetylamino)-hexanoic acid methyl ester**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and L-lysine methyl ester dihydrochloride (Bachem) according to the method described in Example 2/c. MS (EI) 638.2 (MH⁺).

10

Example 46**(S)-2-(2-{4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetylamino)-succinamic acid methyl ester**

15

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and L-asparagine methyl ester hydrochloride (Bachem) according to the method described in Example 2/c. MS (EI) 666.2 (MH⁺).

20

Example 47**4-(2-Phenoxy-phenylsulfamoyl)-N-[(3-piperidin-1-yl-propylcarbamoyl)-methyl]-benzamide**

25 a) [4-(2-Phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid ethyl ester

The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic acid (Example 5/a) and glycine ethyl ester hydrochloride (Aldrich) according to the method described in Example 1/d. MS (EI) 455.2 (MH⁺).

30

b) [4-(2-Phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid ethyl ester according to the method described in Example 2/b. MS (EI) 427.2 (MH⁺).

5 c) 4-(2-Phenoxy-phenylsulfamoyl)-N-[(3-piperidin-1-yl-propylcarbamoyl)-methyl]-benzamide

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid and 3-piperidin-1-yl-propylamine (EMKA-Chemie) according to the method described in Example 2/c. MS (EI) 551.2 (MH⁺).

10

Example 48

N-[(3-[1,4']Bipiperidinyl-1'-yl-propylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 3-[1,4']bipiperidinyl-1'-yl-propylamine trihydrochloride (Reference Example 3) according to the method described in Example 2/c. MS (EI) 634.2 (MH⁺).

Example 49

20 **N-[(4-[1,4']Bipiperidinyl-1'-yl-phenylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 4-[1,4']bipiperidinyl-1'-yl-phenylamine [*J. Med. Chem.* **46** (2003) 1803-1806] according to the method described in Example 2/c. MS (EI) 668.4 (MH⁺).

25

Example 50

trans-4-(2-Phenoxy-phenylsulfamoyl)-N-{[4-(2-pyrrolidin-1-yl-ethyl)-cyclohexyl-carbamoyl]-methyl}-benzamide

30 The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and trans-4-(2-pyrrolidin-1-yl-ethyl)-

cyclohexylamine dihydrochloride (Reference Example 4) according to the method described in Example 2/c. MS (EI) 605.2 (MH⁺).

Example 51

5 **4-(2-Phenoxy-phenylsulfamoyl)-N-{[3-(4-pyridin-4-yl-piperazin-1-yl)-propylcarbamoyl]-methyl}-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 2-(4-pyridin-4-yl-piperazin-1-yl)-propylamine (Reference Example 8) according to the method described in Example 2/c.
10 MS (EI) 629.2 (MH⁺).

Example 52

N-{[(2-Dimethylamino-ethyl)-methyl-carbamoyl]-methyl}-4-(2-phenoxy-phenylsulfamoyl)-benzamide

15 The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and *N,N,N'*-trimethylethylenediamine (Aldrich) according to the method described in Example 2/c. MS (EI) 511.2 (MH⁺).

Example 53

20 **N-[(2-Methylamino-ethylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide hydrochloride**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and (2-amino-ethyl)-methyl-carbamic acid *tert*-butyl ester (Fluka) according to the method described in Example 34. MS (EI)
25 483.2 (MH⁺).

Example 54

N-[(3-Dimethylamino-propylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide

30 The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 3-dimethylamino-1-propylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 511.2 (MH⁺).

Example 55**N-[(3-Diethylamino-propylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

5 The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 3-diethylamino-1-propylamine (Fluka) according to the method described in Example 2/c. MS (EI) 539.2 (MH⁺).

Example 56

10 **N-[(3-(2-Methyl-piperidin-1-yl)-propylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

 The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 3-(2-methyl-piperidin-1-yl)-propylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 565.2 (MH⁺).

15

Example 57**N-[(3-Imidazol-1-yl-propylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

 The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 3-imidazol-1-yl-propylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 534.2 (MH⁺).

20

Example 58

25 **4-(2-Phenoxy-phenylsulfamoyl)-N-[(2-pyrrolidin-1-yl-ethylcarbamoyl)-methyl]-benzamide**

 The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 2-pyrrolidin-1-yl-ethylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 523.2 (MH⁺).

30

Example 59**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(4-piperidin-4-yl-butylcarbamoyl)-methyl]-benzamide hydrochloride**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 4-(4-amino-butyl)-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 5) according to the method described in Example 34. MS (EI) 634.2 (MH⁺).

5

Example 60**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-(piperidin-4-ylcarbamoylmethyl)-benzamide hydrochloride**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 4-amino-piperidine-1-carboxylic acid *tert*-butyl ester (Fluka) according to the method described in Example 34. MS (EI) 578.2 (MH⁺).

Example 61**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(3-piperidin-4-yl-propylcarbamoyl)-methyl]-benzamide hydrochloride**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 4-(3-amino-propyl)-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 6) according to the method described in Example 34. MS (EI) 620.2 (MH⁺).

Example 62**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(4-piperidin-1-yl-cyclohexyl-carbamoyl)-methyl]-benzamide**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 4-piperidin-1-yl-cyclohexylamine [*J. Am. Chem. Soc.* **68** (1946) 1296] according to the method described in Example 2/c. MS (EI) 660.2 (MH⁺).

Example 63**4-[2-(2,4-Dichloro-phenoxy)-phenylsulfamoyl]-N-[(4-piperidin-1-yl-butylcarbamoyl)-methyl]-benzamide**

The title compound was prepared from {4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 2/b) and 4-piperidin-1-yl-butylamine [*J. Med. Chem.* **45** (2002) 1128-1141] according to the method described in Example 2/c. MS (EI) 634.2 (MH⁺).

5

Example 64**N-{[(Piperidin-4-ylmethyl)-carbamoyl]-methyl}-4-[2-(4-trifluoromethyl-phenoxy)-phenylsulfamoyl]-benzamide hydrochloride****a) 4-[2-(4-Trifluormethyl-phenoxy)-phenylsulfamoyl]-benzoic acid**

10 The title compound was prepared from 2-(4-trifluoromethyl-phenoxy)-phenylamine [*J. Chem. Soc. Perkin Trans. 1.* (1976) 1279-1285] according to the method described in Example 3/a. MS (EI) 438.0 (MH⁺).

b) N-{[(Piperidin-4-ylmethyl)-carbamoyl]-methyl}-4-[2-(4-trifluoromethyl-phenoxy)-phenylsulfamoyl]-benzamide hydrochloride

15

The title compound was prepared from 4-[2-(4-trifluormethyl-phenoxy)-phenylsulfamoyl]-benzoic acid and 4-[(2-amino-acetylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method described in Example 34. MS (EI) 591.2 (MH⁺).

20

Example 65**N-{[(Piperidin-4-ylmethyl)-carbamoyl]-methyl}-4-[2-(4-trifluoromethoxy-phenoxy)-phenylsulfamoyl]-benzamide hydrochloride****a) 4-[2-(4-Trifluormethoxy-phenoxy)-phenylsulfamoyl]-benzoic acid**

25 The title compound was prepared from 2-(4-trifluoromethoxy-phenoxy)-phenylamine [*J. Med. Chem.* **13** (1970) 295-297] according to method described in Example 3/a. MS (EI) 454.1 (MH⁺).

b) N-{[(Piperidin-4-ylmethyl)-carbamoyl]-methyl}-4-[2-(4-trifluoromethoxy-phenoxy)-phenylsulfamoyl]-benzamide hydrochloride

30

The title compound was prepared from 4-[2-(4-trifluormethoxy-phenoxy)-phenylsulfamoyl]-benzoic acid and 4-[(2-amino-acetylamino)-methyl]-piperidine-1-

carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method described in Example 34. MS (EI) 607.2 (MH⁺).

Example 66

5 **4-(2-Phenoxy-phenylsulfamoyl)-N-(piperidin-4-ylcarbamoylmethyl)-benzamide hydrochloride**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 4-amino-piperidine-1-carboxylic acid *tert*-butyl ester (Aldrich) according to the method described in Example 34. MS (EI)
10 509.2 (MH⁺).

Example 67

(S)-6-Amino-2-{2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetylamino}-hexanoic acid methyl ester hydrochloride

15 The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and *N*-(*tert*-butoxycarbonyl)-L-lysine methyl ester hydrochloride (Fluka) according to the method described in Example 34. MS (EI) 569.2 (MH⁺).

20 **Example 68**

N-Carbamoylmethyl-4-(2-phenoxy-phenylsulfamoyl)-benzamide

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and ammonium carbonate according to the method described in Example 2/c. MS (EI) 426.2 (MH⁺).

25

Example 69

N-[(2-Hydroxy-ethylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and ethanolamine hydrochloride (Aldrich)
30 according to the method described in Example 2/c. MS (EI) 470.2 (MH⁺).

Example 70**N-[(3-Hydroxy-propylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 3-amino-1-propanol hydrochloride (Aldrich) according to the method described in Example 2/c. MS (EI) 484.2 (MH⁺).

Example 71**N-[(4-Hydroxy-butylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 4-amino-1-butanol hydrochloride (Aldrich) according to the method described in Example 2/c. MS (EI) 498.2 (MH⁺).

Example 72**N-Cycloheptylcarbamoylmethyl-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and cycloheptylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 522.2 (MH⁺).

20

Example 73**N-[(4-Cyanomethyl-phenylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and (4-amino-phenyl)-acetonitrile (Aldrich) according to the method described in Example 2/c. MS (EI) 541.2 (MH⁺).

Example 74**N-Cyclohexylcarbamoylmethyl-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and cyclohexylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 508.2 (MH⁺).

30

Example 75**N-Cyclopentylcarbamoylmethyl-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and cyclopentylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 494.2 (MH⁺).

Example 76**N-[(2-Acetyl-amino-phenylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and N-(2-amino-phenyl)-acetamide (Aldrich) according to the method described in Example 2/c. MS (EI) 559.2 (MH⁺).

Example 77**4-(2-Benzoyl-phenylsulfamoyl)-N-cyclohexylcarbamoylmethyl-benzamide****a) 4-(2-Benzoyl-phenylsulfamoyl)-benzoic acid**

The title compound was prepared from 2-amino-benzophenone according to the method described in Example 1/c. MS (EI) 382.2 (MH⁺).

b) [4-(2-Benzoyl-phenylsulfamoyl)-benzoylamino]-acetic acid ethyl ester

The title compound was prepared from 4-(2-benzoyl-phenylsulfamoyl)-benzoic acid and glycine ethyl ester hydrochloride (Aldrich) according to the method described in Example 1/d. MS (EI) 867.2 (MH⁺).

c) [4-(2-Benzoyl-phenylsulfamoyl)-benzoylamino]-acetic acid

The title compound was prepared from [4-(2-benzoyl-phenylsulfamoyl)-benzoylamino]-acetic acid ethyl ester according to the method described in Example 1/e. MS (EI) 439.2 (MH⁺).

d) 4-(2-Benzoyl-phenylsulfamoyl)-N-cyclohexylcarbamoylmethyl-benzamide

The title compound was prepared from [4-(2-benzoyl-phenylsulfamoyl)-benzoylamino]-acetic acid and cyclohexylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 520.2 (MH⁺).

5 **Example 78**

4-(2-Benzoyl-phenylsulfamoyl)-N-[(4-[1,4']bipiperidinyl-1'-yl-phenylcarbamoyl)-methyl]-benzamide

The title compound was prepared from [4-(2-benzoyl-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 77/c) and 4-[1,4']bipiperidinyl-1'-yl-phenylamine
10 [*J. Med. Chem.* **46** (2003) 1803-1806] according to the method described in Example 2/c. MS (EI) 680.2 (MH⁺).

Example 79

15 **trans-4-(2-Benzoyl-phenylsulfamoyl)-N-{[4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylcarbamoyl]-methyl}-benzamide**

The title compound was prepared from [4-(2-benzoyl-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 77/c) and trans-4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylamine dihydrochloride (Reference Example 4) according to the method described in Example 2/c. MS (EI) 617.2 (MH⁺).

20

Example 80

4-(2-Benzoyl-phenylsulfamoyl)-N-(piperidin-4-ylcarbamoylmethyl)-benzamide hydrochloride

The title compound was prepared from [4-(2-benzoyl-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 77/c) and 4-amino-piperidine-1-carboxylic acid
25 *tert*-butyl ester (Fluka) according to the method described in Example 34. MS (EI) 521.2 (MH⁺).

Example 81

30 **4-(2-Benzoyl-phenylsulfamoyl)-N-[(4-piperidin-1-yl-cyclohexylcarbamoyl)-methyl]-benzamide**

The title compound was prepared from [4-(2-benzoyl-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 77/c) and 4-piperidin-1-yl-cyclohexylamine [*J. Am. Chem. Soc.* **68** (1946) 1296] according to the method described in Example 2/c. MS (EI) 603.2 (MH⁺).

5

Example 82**N-{1-[(1-Ethyl-piperidin-4-ylmethyl)-carbamoyl]-1-methyl-ethyl}-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from 2-methyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid (Example 20/b) and C-(1-ethyl-piperidin-4-yl)-methylamine [*Eur. J. Med. Chem. Chim. Ther.* **34** (1999) 329-342] according to the method described in Example 1/d. MS (EI) 579.2 (MH⁺).

Example 83**4-(2-Phenoxy-phenylsulfamoyl)-N-[(4-piperidin-4-yl-butylcarbamoyl)-methyl]-benzamide hydrochloride**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 4-(4-amino-butyl)-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 5) according to the method described in Example 34. MS (EI) 565.2 (MH⁺).

20

Example 84**N-{(S)-2-(4-Hydroxy-phenyl)-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl}-4-(2-phenoxy-phenylsulfamoyl)-benzamide trifluoroacetate**

a) (S)-3-(4-Hydroxy-phenyl)-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid methyl ester

25

The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic acid (Example 5/a) and L-tyrosine methyl ester (Aldrich) according to the method described in Example 1/d. MS (EI) 547.2 (MH⁺).

30

b) (S)-3-(4-Hydroxy-phenyl)-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid

-65 -

The title compound was prepared from (S)-3-(4-hydroxy-phenyl)-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid methyl ester according to the method described in Example 2/b. MS (EI) 533.2 (MH⁺).

5 c) 4-((S)-3-(4-Hydroxy-phenyl)-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionylamino)-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from (S)-3-(4-hydroxy-phenyl)-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid and 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in
10 Example 1/d. MS (EI) 751.2 (M+Na⁺).

d) N-((S)-2-(4-Hydroxy-phenyl)-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl)-4-(2-phenoxy-phenylsulfamoyl)-benzamide trifluoroacetate

The title compound was prepared from 4-((S)-3-(4-hydroxy-phenyl)-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionylamino)-methyl)-piperidine-1-
15 carboxylic acid *tert*-butyl ester according to the method described in Example 3/c. MS (EI) 629.2 (MH⁺).

Example 85

20 N-((S)-5-Amino-1-[(piperidin-4-ylmethyl)-carbamoyl]-pentyl)-4-(2-phenoxy-phenylsulfamoyl)-benzamide ditrifluoroacetate

a) (S)-6-*tert*-Butoxycarbonylamino-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-hexanoic acid methyl ester

The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic acid (Example 5/a) and *N*-(*tert*-butoxycarbonyl)-L-lysine methyl ester [*Bull. Chem. Soc. Jpn.* 37 (1964) 1471-1477] according to the method described in Example 1/d. MS (EI)
25 634.4 (M+Na⁺).

b) (S)-6-*tert*-Butoxycarbonylamino-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-hexanoic acid
30

The title compound was prepared from (*S*)-6-*tert*-butoxycarbonylamino-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-hexanoic acid methyl ester according to the method described in Example 2/b. MS (EI) 598.2 (MH^+).

- 5 c) 4-({(*S*)-6-*tert*-Butoxycarbonylamino-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-hexanoylamino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from (*S*)-6-*tert*-butoxycarbonylamino-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-hexanoic acid and 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in
10 Example 1/d. MS (EI) 816.2 ($M+Na^+$).

- d) *N*-{(*S*)-5-Amino-1-[(piperidin-4-ylmethyl)-carbamoyl]-pentyl}-4-(2-phenoxy-phenylsulfamoyl)-benzamide ditrifluoroacetate

The title compound was prepared from 4-({(*S*)-6-*tert*-butoxycarbonylamino-2-
15 [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-hexanoylamino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 3/c. MS (EI) 594.2 (MH^+).

Example 86

- 20 **4-(2-Phenoxy-phenylsulfamoyl)-*N*-{1-[(piperidin-4-ylmethyl)-carbamoyl]-cyclopropyl}-benzamide trifluoroacetate**

- a) 1-[4-(2-Phenoxy-phenylsulfamoyl)-benzoylamino]-cyclopropanecarboxylic acid methyl ester

The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic
25 acid (Example 5/a) and methyl 1-amino-cyclopropane-carboxylate hydrochloride (Sigma) according to the method described in Example 1/d. MS (EI) 467.1 (MH^+).

- b) 1-[4-(2-Phenoxy-phenylsulfamoyl)-benzoylamino]-cyclopropanecarboxylic acid

The title compound was prepared from 1-[4-(2-phenoxy-phenylsulfamoyl)-
30 benzoylamino]-cyclopropanecarboxylic acid methyl ester according to the method described in Example 2/b. MS (EI) 453.1 (MH^+).

c) 4-[(1-[4-(2-Phenoxy-phenylsulfamoyl)-benzoylamino]-cyclopropanecarbonyl}-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 1-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-cyclopropanecarboxylic acid and 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/d. MS (EI) 671.2 ($M+Na^+$).

d) 4-(2-Phenoxy-phenylsulfamoyl)-*N*-{1-[(piperidin-4-ylmethyl)-carbamoyl]-cyclopropyl}-benzamide trifluoroacetate

The title compound was prepared from 4-[(1-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-cyclopropanecarbonyl}-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 3/c. MS (EI) 549.2 (MH^+).

Example 87

4-(2-Phenoxy-phenylsulfamoyl)-*N*-phenylcarbamoylmethyl-benzamide

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and aniline according to the method described in Example 2/c. MS (EI) 502.1 (MH^+).

Example 88

4-(2-Phenoxy-phenylsulfamoyl)-*N*-[(5-trifluoromethyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-methyl]-benzamide

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 5-trifluoromethyl-[1,3,4]thiadiazol-2-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 578.2 (MH^+).

Example 89

4-(2-Phenoxy-phenylsulfamoyl)-*N*-[(1,3,4]thiadiazol-2-ylcarbamoylmethyl)-benzamide

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and [1,3,4]thiadiazol-2-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 510.2 (MH⁺).

5 **Example 90**

N-[(1*H*-Indol-6-ylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 1*H*-indol-6-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 541.2 (MH⁺).

10

Example 91

N-[(1*H*-Benzoimidazol-2-ylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 1*H*-benzimidazol-2-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 542.2 (MH⁺).

Example 92

20 **N-[(2,2-Difluoro-benzo[1,3]dioxol-4-ylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 2,2-difluoro-benzo[1,3]dioxol-4-ylamine (ABCR) according to the method described in Example 2/c. MS (EI) 582.2 (MH⁺).

25 **Example 93**

N-[(4-Methyl-thiazol-2-ylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 4-methyl-thiazol-2-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 523.2 (MH⁺).

30

Example 94

N-(Benzothiazol-2-ylcarbamoylmethyl)-4-(2-phenoxy-phenylsulfamoyl)-benzamide

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and benzothiazol-2-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 559.2 (MH⁺).

5

Example 95**N-[(4-Cyano-1H-pyrazol-3-ylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 3-amino-1H-pyrazole-4-carbonitrile (Aldrich) according to the method described in Example 2/c. MS (EI) 517.2 (MH⁺).

10

Example 96**N-[(5-Methyl-thiazol-2-ylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

15

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 5-methyl-thiazol-2-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 523.2 (MH⁺).

20

Example 97**N-[(5-Methyl-2H-pyrazol-3-ylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

25

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 5-methyl-2H-pyrazol-3-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 506.1 (MH⁺).

Example 98**N-[(6-Acetyl-amino-pyridin-3-ylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

30

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and N-(5-amino-pyridin-2-yl)-acetamide (Aldrich) according to the method described in Example 2/c. MS (EI) 560.1 (MH⁺).

Example 99**N-[(1*H*-Indol-4-ylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 1*H*-indol-4-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 541.1 (MH⁺).

Example 100**N-(Benzothiazol-6-ylcarbamoylmethyl)-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and benzothiazol-6-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 559.2 (MH⁺).

Example 101**N-[(1*H*-Indol-5-ylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 1*H*-indol-5-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 541.2 (MH⁺).

Example 102**N-[(3,5-Dimethyl-isoxazol-4-ylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and 3,5-dimethyl-isoxazol-4-ylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 521.2 (MH⁺).

Example 103**4-(2-Phenylamino-phenylsulfamoyl)-N-[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride****a) 4-(2-Phenylamino-phenylsulfamoyl)-benzoic acid**

The title compound was prepared from 2-amino-diphenylamine (Aldrich) according to the method described in Example 1/c. MS (EI) 369.2 (MH⁺).

b) 4-({2-[4-(2-Phenylamino-phenylsulfamoyl)-benzoylamino]-acetyl-amino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester

The title compound was prepared from 4-(2-phenylamino-phenylsulfamoyl)-benzoic acid and 4-[(2-amino-acetyl-amino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (Reference Example 1) according to the method described in Example 1/d. MS (EI) 622.2 (MH⁺).

c) 4-(2-Phenylamino-phenylsulfamoyl)-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride

The title compound was prepared from 4-({2-[4-(2-phenylamino-phenylsulfamoyl)-benzoylamino]-acetyl-amino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/e. MS (EI) 522.2 (MH⁺).

Example 104

N-{(S)-2-Hydroxy-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl}-4-(2-phenoxy-phenylsulfamoyl)-benzamide trifluoroacetate

a) (S)-3-Hydroxy-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid methyl ester

The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic acid (Example 5/a) and L-serine methyl ester hydrochloride (Aldrich) according to the method described Example 1/d.

b) (S)-3-Hydroxy-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid

The title compound was prepared from (S)-3-hydroxy-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid methyl ester according to the method described Example 2/b. MS (EI) 457.3 (MH⁺).

c) 4-({(S)-3-Hydroxy-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionyl-amino}-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester

-72 -

The title compound was prepared from (*S*)-3-hydroxy-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionic acid and 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/d. MS (EI) 675.2 ($M+Na^+$).

5

d) *N*-{(S)-2-Hydroxy-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl}-4-(2-phenoxy-phenylsulfamoyl)-benzamide trifluoroacetate

The title compound was prepared from 4-((*S*)-3-hydroxy-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-propionylamino)-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 3/c. MS (EI) 553.2 (MH^+).

10

Example 105

(S)-2-[4-(2-Phenoxy-phenylsulfamoyl)-benzoylamino]-pentanedioic acid 5-amide 1-[(piperidin-4-ylmethyl)-amide] hydrochloride

15

a) (S)-4-Carbamoyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyric acid methyl ester

20

The title compound was prepared from 4-(2-phenoxy-phenylsulfamoyl)-benzoic acid (Example 5/a) and L-glutamine methyl ester hydrochloride (Senn Chemicals) according to the method described Example 1/d.

b) (S)-4-Carbamoyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyric acid

25

The title compound was prepared from (*S*)-4-carbamoyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyric acid methyl ester according to the method described Example 2/b. MS (EI) 498.3 (MH^+).

c) 4-((S)-4-Carbamoyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyrylamino)-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester

30

The title compound was prepared from (*S*)-4-carbamoyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyric acid and 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester according to the method described in Example 1/d. MS (EI) 716.2 ($M+Na^+$).

d) (S)-2-[4-(2-Phenoxy-phenylsulfamoyl)-benzoylamino]-pentanedioic acid 5-amide 1-[(piperidin-4-ylmethyl)-amide] hydrochloride

The title compound was prepared from 4-({(S)-4-carbamoyl-2-[4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-butyrylamino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester according to the method described in Example 1/e. MS (EI) 594.5 (MH⁺).

Example 106

10 **N-Cyclooctylcarbamoylmethyl-4-(2-phenoxy-phenylsulfamoyl)-benzamide**

The title compound was prepared from [4-(2-phenoxy-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 47/b) and cyclooctylamine (Aldrich) according to the method described in Example 2/c. MS (EI) 536.2 (MH⁺).

15 **Example 107**

4-(2-Benzoyl-phenylsulfamoyl)-N-[(2-piperidin-4-yl-ethylcarbamoyl)-methyl]-benzamide hydrochloride

The title compound was prepared from [4-(2-benzoyl-phenylsulfamoyl)-benzoylamino]-acetic acid (Example 77/c) and 4-(2-amino-ethyl)-piperidine-1-carboxylic acid tert-butyl ester [*Bioorg. Med. Chem. Lett.*; **13** (2003) 2167-2172.] according to the method described in Example 34. MS (EI) 549.2 (MH⁺).

Example 108

25 **4-[2-(2,4-Dichloro-benzoyl)-phenylsulfamoyl]-N-[(2-piperidin-4-yl-ethylcarbamoyl)-methyl]-benzamide hydrochloride**

a) 4-[2-(2,4-Dichloro-benzoyl)-phenylsulfamoyl]-benzoic acid

The title compound was prepared from (2-amino-phenyl)-(2,4-dichloro-phenyl)-methanone [*Synthesis*, (1980) 677-688] and 4-chlorosulfonyl-benzoic acid according to the method described in Example 1/c. MS (EI) 451 (MH⁺).

30

b) {4-[2-(2,4-Dichloro-benzoyl)-phenylsulfamoyl]-benzoylamino}-acetic acid ethyl ester

The title compound was prepared from 4-[2-(2,4-dichloro-benzoyl)-phenylsulfamoyl]-benzoic acid and glycine ethyl ester hydrochloride according to the method described in Example 1/d. MS (EI) 536.1 (MH^+).

5 c) {4-[2-(2,4-Dichloro-benzoyl)-phenylsulfamoyl]-benzoylamino}-acetic acid

The title compound was prepared from {4-[2-(2,4-dichloro-benzoyl)-phenylsulfamoyl]-benzoylamino}-acetic acid ethyl ester according to the method described in Example 2/b. MS (EI) 508 (MH^+).

10 d) 4-[2-(2,4-Dichloro-benzoyl)-phenylsulfamoyl]-N-[(2-piperidin-4-yl-ethylcarbamoyl)-methyl]-benzamide hydrochloride

The title compound was prepared from {4-[2-(2,4-dichloro-benzoyl)-phenylsulfamoyl]-benzoylamino}-acetic acid and 4-(2-amino-ethyl)-piperidine-1-carboxylic acid tert-butyl ester [*Bioorg. Med. Chem. Lett.*; **13** (2003) 2167-2172.] according to the method described in Example 34. MS (EI) 618.4 (MH^+).

Example 109

trans-4-[2-(2,4-Dichloro-benzoyl)-phenylsulfamoyl]-N-{[4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylcarbamoyl]-methyl}-benzamide

20 The title compound was prepared from {4-[2-(2,4-dichloro-benzoyl)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 108/c) and trans-4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylamine dihydrochloride (Reference Example 4) according to the method described in Example 2/c. MS (EI) 686.2 (MH^+).

25 **Example 110**

4-[2-(2,4-Dichloro-benzoyl)-phenylsulfamoyl]-N-(piperidin-4-ylcarbamoylmethyl)-benzamide hydrochloride

The title compound was prepared from {4-[2-(2,4-dichloro-benzoyl)-phenylsulfamoyl]-benzoylamino}-acetic acid (Example 108/c) and 4-amino-piperidine-1-carboxylic acid *tert*-butyl ester (Fluka) according to the method described in Example 34. MS (EI) 589.3 (MH^+).

Example 111**trans-4-[2-(2-Chloro-4-fluoro-phenoxy)-phenylsulfamoyl]-N-{[4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylcarbamoyl]-methyl}-benzamide****a) 2-Chloro-4-fluoro-1-(2-nitro-phenoxy)-benzene**

5 The title compound was prepared from 2-chloro-4-fluoro-phenol according to the method described in Example 1/a.

b) 2-(2-Chloro-4-fluoro-phenoxy)-phenylamine

 The title compound was prepared from 2-chloro-4-fluoro-1-(2-nitro-phenoxy)-
10 benzene according to the method described in Example 1/b.

c) 4-[2-(2-Chloro-4-fluoro-phenoxy)-phenylsulfamoyl]-benzoic acid

 The title compound was prepared from 2-(2-chloro-4-fluoro-phenoxy)-phenylamine according to the method described in Example 1/c. MS (EI) 422.1 (MH⁺).

15

d) {4-[2-(2-Chloro-4-fluoro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid ethyl ester

 The title compound was prepared from 4-[2-(2-chloro-4-fluoro-phenoxy)-phenylsulfamoyl]-benzoic acid and glycine ethyl ester hydrochloride according to the
20 method described in Example 1/d.

e) {4-[2-(2-Chloro-4-fluoro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid

 The title compound was prepared from {4-[2-(2-chloro-4-fluoro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid ethyl ester according to the method
25 described in Example 2/b. MS (EI) 479 (MH⁺).

f) trans-4-[2-(2-Chloro-4-fluoro-phenoxy)-phenylsulfamoyl]-N-{[4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylcarbamoyl]-methyl}-benzamide

 The title compound was prepared from {4-[2-(2-chloro-4-fluoro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid and trans-4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylamine dihydrochloride (Reference Example 4) according to the method
30 described in Example 2/c. MS (EI) 657.4 (MH⁺).

Example 112**trans-4-[2-(4-Bromo-2-chloro-phenoxy)-phenylsulfamoyl]-N-{[4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylcarbamoyl]-methyl}-benzamide**5 **a) 4-Bromo-2-chloro-1-(2-nitro-phenoxy)-benzene**

The title compound was prepared from 4-bromo-2-chloro-phenol according to the method described in Example 1/a. MS (EI) 329.3 (MH⁺).

b) **2-(4-Bromo-2-chloro-phenoxy)-phenylamine**

10 The title compound was prepared from 4-bromo-2-chloro-1-(2-nitro-phenoxy)-benzene according to the method described in Example 1/b. MS (EI) 300.2 (MH⁺).

c) **4-[2-(4-Bromo-2-chloro-phenoxy)-phenylsulfamoyl]-benzoic acid**

15 The title compound was prepared from 2-(4-bromo-2-chloro-phenoxy)-phenylamine according to the method described in Example 1/c. MS (EI) 483.4 (MH⁺).

d) **{4-[2-(4-Bromo-2-chloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid ethyl ester**

20 The title compound was prepared from 4-[2-(4-bromo-2-chloro-phenoxy)-phenylsulfamoyl]-benzoic acid and glycine ethyl ester hydrochloride according to the method described in Example 1/d.

e) **{4-[2-(4-Bromo-2-chloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid**

25 The title compound was prepared from {4-[2-(4-bromo-2-chloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid ethyl ester according to the method described in Example 2/b. MS (EI) 541.1 (MH⁺).

f) **trans-4-[2-(4-Bromo-2-chloro-phenoxy)-phenylsulfamoyl]-N-{[4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylcarbamoyl]-methyl}-benzamide**

30 The title compound was prepared from {4-[2-(4-bromo-2-chloro-phenoxy)-phenylsulfamoyl]-benzoylamino}-acetic acid and trans-4-(2-pyrrolidin-1-yl-ethyl)-

cyclohexylamine dihydrochloride (Reference Example 4) according to the method described in Example 2/c. MS (EI) 719.4 (MH⁺).

Example 113

5 Preparation of pharmaceutical compositions:

a) Tablets:

0.01-50 % of active ingredient of formula (I), 15-50 % of lactose, 15-50 % of potato starch, 5-15 % of polyvinyl pyrrolidone, 1-5 % of talc, 0.01-3 % of magnesium stearate, 1-3 % of colloid silicon dioxide and 2-7 % of ultraamylopectin were mixed,
10 then granulated by wet granulation and pressed to tablets.

b) Dragées, filmcoated tablets:

The tablets made according to the method described above were coated by a layer consisting of entero- or gastrosolvent film, or of sugar and talc. The dragées were polished by a mixture of beeswax and carnuba wax.

15 c) Capsules:

0.01-50 % of active ingredient of formula (I), 1-5 % of sodium lauryl sulfate, 15-50 % of starch, 15-50 % of lactose, 1-3 % of colloid silicon dioxide and 0.01-3 % of magnesium stearate were thoroughly mixed, the mixture was passed through a sieve and filled in hard gelatin capsules.

20 d) Suspensions:

Ingredients: 0.01-15 % of active ingredient of formula (I), 0.1-2 % of sodium hydroxide, 0.1-3 % of citric acid, 0.05-0.2 % of nipagin (sodium methyl 4-hydroxybenzoate), 0.005-0.02 % of nipasol, 0.01-0.5 % of carbopol (polyacrylic acid), 0.1-5 % of 96 % ethanol, 0.1-1 % of flavoring agent, 20-70 % of sorbitol (70 % aqueous
25 solution) and 30-50 % of distilled water.

To solution of nipagin and citric acid in 20 ml of distilled water, carbopol was added in small portions under vigorous stirring, and the solution was left to stand for 10-12 h. Then the sodium hydroxide in 1 ml of distilled water, the aqueous solution of sorbitol and finally the ethanolic raspberry flavor were added with stirring. To this
30 carrier the active ingredient was added in small portions and suspended with an immersing homogenizator. Finally the suspension was filled up to the desired final

-78 -

volume with distilled water and the suspension syrup was passed through a colloid milling equipment.

e) Suppositories:


For each suppository 0.01-15% of active ingredient of formula (I) and 1-20% of
5 lactose were thoroughly mixed, then 50-95% of adeps pro suppository (for example Witepsol 4) was melted, cooled to 35 °C and the mixture of active ingredient and lactose was mixed in it with homogenizator. The obtained mixture was mould in cooled forms.

f) Lyophilized powder ampoule compositions:

10 A 5 % solution of mannitol or lactose was made with bidistilled water for injection use, and the solution was filtered so as to have sterile solution. A 0.01-5 % solution of the active ingredient of formula (I) was also made with bidistilled water for injection use, and this solution was filtered so as to have sterile solution. These two solutions were mixed under aseptic conditions, filled in 1 ml portions into ampoules, the
15 content of the ampoules was lyophilized, and the ampoules were sealed under nitrogen. The contents of the ampoules were dissolved in sterile water or 0.9 % (physiological) sterile aqueous sodium chloride solution before administration.

Claims

1. New bradykinin B1 receptor antagonist phenylsulfamoyl benzamide derivatives of formula (I)



(I)

wherein

- R^1 is hydrogen atom or C_1 - C_4 alkyl group;
- R^2 is selected from (1) hydrogen atom; (2) C_1 - C_6 straight or branched alkyl group;
- (3) $-(CH_2)_n-NH_2$; (4) $-(CH_2)_n-OH$; (5) $-(CH_2)_n-CO-NH_2$; (6) $-(CH_2)_n-COOR^c$;
- (7) benzyl optionally substituted with one or more hydroxy group or halogen atom; or
- R^1 , R^2 and the carbon atom to which they are both attached together form a 3-7 membered cycloalkyl ring;
- R^3 is (1) hydrogen atom, (2) C_1 - C_8 straight or branched alkyl group, optionally substituted with one or more substituents independently selected from amino, hydroxy, 1*H*-imidazol-4-yl, $-NR^aR^b$, $-COOR^c$, $-NH-C(=NH)-NH_2$, $-CO-NH_2$ group;
- R^4 is (1) hydrogen atom, (2) $-(CH_2)_n-NR^aR^b$ group; (3) $-(CH_2)_m-X-P$ group;
- R^5 , R^6 and R^7 are independently of each other hydrogen atom, halogen atom, cyano, nitro, amino, or amino substituted with one or more C_1 - C_4 alkyl group; trifluoromethyl; C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $-C(=O)-NH_2$, C_1 - C_4 alkoxycarbonyl, trifluoromethoxy or hydroxy group;
- R^8 is hydrogen atom or C_1 - C_4 alkyl group;

-80 -

- Z is selected from (1) single bond; (2) oxygen atom; (3) CH₂ group; (4) CO group; (5) NR^c group; (6) S atom; (7) SO₂ group;
- n is an integer from 1 to 6;
- m is an integer from 0 to 6;
- 5 X is selected from (1) single bond; (2) oxygen atom; (3) -CO-NR^c group; (4) CO or SO₂ group;
- P is selected from (1) phenyl group, optionally substituted with one or more halogen atom, hydroxy, -(CH₂)_m-CN, -O-CO-NR^cR^c, -NH-CO-R^c, C₁-C₄ alkyl, C₁-C₄ alkoxy, cyano, amino, [1,4']bipiperidiny-1'-yl or -(CH₂)_n-NH-C(=NH)-NH₂ group; (2) a saturated, partially unsaturated or aromatic 4-7 membered ring containing 1-3 heteroatom selected from O, S, SO₂ and N; wherein said ring is optionally substituted with one or more halogen atom, oxo, hydroxy, cyano, amino, trifluoromethyl, -NH-CO-R^c, -C(=NH)-NH₂, C₁-C₄ alkyl, pyridin-4-yl, piperidin-1-yl or pyridine-2-yl group; (3) a saturated, partially unsaturated or aromatic 8-10 membered bicyclic ring system containing 1-3 heteroatom selected from O, S, SO₂ and N; wherein said ring system is optionally substituted with one or more halogen atom, oxo, hydroxy, cyano, amino, -NH-CO-R^c, trifluoromethyl or C₁-C₄ alkyl group; (4) C₅-C₈ cycloalkyl group, optionally substituted with -(CH₂)_m-NR^aR^b group;
- 15
- 20 R^a and R^b are (1) hydrogen atom; (2) straight or branched C₁-C₆ alkyl group; (3) R^a, R^b and the nitrogen atom to which they are both attached together form a saturated, partially unsaturated or aromatic 4-7 membered ring containing 0-3 heteroatom (in addition to the nitrogen atom to which R^a and R^b attached) selected from O, S, SO₂ and N; wherein said ring is optionally substituted with one or more halogen atom, oxo, cyano, hydroxy or C₁-C₄ alkyl group;
- 25 R^c is hydrogen atom or C₁-C₄ alkyl group;
- and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof.
2. A compound of Claim 1 selected from the group of 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-N-[[piperidin-4-ylmethyl]-carbamoyl]-methyl}-benzamide hydrochloride; 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-N-[(3-piperidin-1-yl-propylcarbamoyl)-methyl]-benzamide; 4-[2-(4-bromo-phenoxy)-phenylsulfamoyl]-N-[[piperidin-4-ylmethyl]-carbamoyl]-methyl}-benzamide
- 30

trifluoroacetate; 4-[2-(4-bromo-phenoxy)-5-fluoro-phenylsulfamoyl]-*N*-
 {[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide mono trifluoroacetate;
 4-(2-phenoxy-phenylsulfamoyl)-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-
 benzamide hydrochloride; 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-{2-
 5 phenyl-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl}-benzamide hydrochloride; 4-
 (5-fluoro-2-phenoxy-phenylsulfamoyl)-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-
 methyl}-benzamide hydrochloride; 4-[2-(2,4-dichloro-phenoxy)-
 phenylsulfamoyl]-*N*-{(S)-1-[(piperidin-4-ylmethyl)-carbamoyl]-ethyl}-benzamide
 hydrochloride; 4-(2-phenoxy-phenylsulfamoyl)-*N*-[(2-piperidin-4-yl-
 10 ethylcarbamoyl)-methyl]-benzamide hydrochloride; 4-[2-(2,4-dichloro-phenoxy)-
 4-methoxy-phenylsulfamoyl]-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-
 benzamide hydrochloride; 4-[2-(4-fluoro-phenoxy)-phenylsulfamoyl]-*N*-
 {[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride; 4-[5-
 fluoro-2-(4-fluoro-phenoxy)-phenylsulfamoyl]-*N*-[(2-piperidin-4-yl-
 15 ethylcarbamoyl)-methyl]-benzamide hydrochloride; *N*-{[(1-carbamimidoyl-
 piperidin-4-ylmethyl)-carbamoyl]-methyl}-4-[2-(2,4-dichloro-phenoxy)-
 phenylsulfamoyl]-benzamide hydrochloride; 4-[5-fluoro-2-(4-fluoro-phenoxy)-
 phenylsulfamoyl]-*N*-{[(2-piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide
 hydrochloride; *N*-[(2-oxo-2-piperazin-1-yl-ethylcarbamoyl)-methyl]-4-(2-
 20 phenoxy-phenylsulfamoyl)-benzamide hydrochloride; 4-(2-benzoyl-
 phenylsulfamoyl)-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide
 hydrochloride; 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-[(2-piperidin-4-
 yl-ethylcarbamoyl)-methyl]-benzamide acetate; 4-[2-(2,4-dichloro-phenoxy)-
 phenylsulfamoyl]-*N*-[(2-piperidin-1-yl-ethylcarbamoyl)-methyl]-benzamide; 4-[2-
 25 (2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-[(3-dimethylamino-
 propylcarbamoyl)-methyl]-benzamide; 4-[2-(2,4-dichloro-phenoxy)-
 phenylsulfamoyl]-*N*-[(3-morpholin-4-yl-propylcarbamoyl)-methyl]-benzamide; 4-
 [2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-{[3-(2-methyl-piperidin-1-yl)-
 propylcarbamoyl]-methyl}-benzamide; 4-[2-(2,4-dichloro-phenoxy)-
 30 phenylsulfamoyl]-*N*-[(3-imidazol-1-yl-propylcarbamoyl)-methyl]-benzamide; 4-
 [2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-[(2-morpholin-4-yl-
 ethylcarbamoyl)-methyl]-benzamide; 4-[2-(2,4-dichloro-phenoxy)-


phenylsulfamoyl]-*N*-[(2-pyrrolidin-1-yl-ethylcarbamoyl)-methyl]-benzamide; 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-[(3-dimethylamino-2,2-dimethyl-propylcarbamoyl)-methyl]-benzamide; 4-[2-(4-bromo-2-chloro-phenoxy)-phenylsulfamoyl]-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide
 5 hydrochloride; 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-[(4-guanidinomethyl-benzylcarbamoyl)-methyl]-benzamide hydrochloride; 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-{[methyl-(2-pyridin-4-yl-ethyl)-carbamoyl]-methyl}-benzamide; *N*-[(3-[1,4']bipiperidiny-1'-yl-propylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide; *N*-[(4-[1,4']bipiperidiny-1'-yl-phenylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide; trans-
 10 4-(2-phenoxy-phenylsulfamoyl)-*N*-{[4-(2-pyrrolidin-1-yl-ethyl)-cyclohexyl-carbamoyl]-methyl}-benzamide; *N*-[(3-dimethylamino-propylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide; *N*-{[3-(2-methyl-piperidin-1-yl)-propylcarbamoyl]-methyl}-4-(2-phenoxy-phenylsulfamoyl)-benzamide; 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-[(4-piperidin-4-yl-
 15 butylcarbamoyl)-methyl]-benzamide hydrochloride; 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-(piperidin-4-ylcarbamoylmethyl)-benzamide hydrochloride; 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-[(3-piperidin-4-yl-propylcarbamoyl)-methyl]-benzamide hydrochloride; 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-[(4-piperidin-1-yl-cyclohexyl-carbamoyl)-methyl]-
 20 benzamide; 4-[2-(2,4-dichloro-phenoxy)-phenylsulfamoyl]-*N*-[(4-piperidin-1-yl-butylcarbamoyl)-methyl]-benzamide; 4-(2-phenoxy-phenylsulfamoyl)-*N*-(piperidin-4-ylcarbamoylmethyl)-benzamide hydrochloride; 4-(2-phenylamino-phenylsulfamoyl)-*N*-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide
 25 hydrochloride or *N*-[(4-cyanomethyl-phenylcarbamoyl)-methyl]-4-(2-phenoxy-phenylsulfamoyl)-benzamide.

3. A process for preparing the compounds of formula (I) as claimed in Claim 1 which comprises

Method a)

- 30 reacting an amine derivative of formula (II)


-83 -



(II)


- wherein the meaning of R^5 , R^6 and R^7 is as described above for the formula (I) – with the sulfonyl chloride of formula (III)

5



(III)


then reacting the so obtained phenylsulfamoyl benzoic acid derivative of formula (IV)



(IV)

10

– wherein the meaning of R^5 , R^6 and R^7 is as defined above – with an amine derivative of formula (V)



(V)


15

– wherein the meaning of R^1 , R^2 , R^3 , R^4 and R^8 is as defined above – to obtain a phenylsulfamoyl benzamide derivative of formula (I) or optical antipodes or racemates and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof.

5

Method b)


Reacting the phenylsulfamoyl benzoic acid derivative of formula (IV) – obtained according to the method described in method a) – with an amino acid derivative of formula (VI)



10

(VI)


– wherein the meaning of R^1 , R^2 and R^8 is as defined above, and R is C_1 - C_4 alkyl group
– and hydrolyzing the so obtained compound of formula (VII)



15

(VII)

- wherein the meaning of R^1 , R^2 , R^5 , R^6 , R^7 , R^8 and R is as defined above – to furnish a carboxylic acid derivative of formula (VIII)



(VIII)

- wherein the meaning of R^1 , R^2 , R^5 , R^6 , R^7 and R^8 is as defined above - finally reacting the latter with an amine derivative of formula (IX)



(IX)

- wherein the meaning of R^3 and R^4 is as defined above — to obtain a phenylsulfamoyl benzamide derivative of formula (I) or optical antipodes or racemates and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof.

4. A process for preparing the compounds of formula (I) as claimed in Claim 1 which comprises transforming a compound of formula (I) into an other compound of formula (I) by introducing new substituents and/or modifying or removing the existing ones, and/or salt formation and/or liberating the compound from salts.
5. A compound of formula (V) is 4-[2-(2-amino-acetyl-amino)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester.
6. A compound of formula (IX) selected from the group of trans-4-(2-pyrrolidin-1-yl-ethyl)-cyclohexylamine dihydrochloride; N-(4-aminomethyl-benzyl)-guanidine dihydrochloride or 2-(4-pyridin-4-yl-piperazin-1-yl)-propylamine.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as claimed in Claim 1 or optical antipodes or racemates or pharmaceutically acceptable salt or hydrate or solvate thereof and one or more pharmaceutically acceptable excipients.
8. Use of a compound of formula (I) as claimed in Claim 1 or optical antipodes or racemates or a pharmaceutically acceptable salt or hydrate or solvate thereof for the manufacture of a medicament for prevention and/or treatment of a condition which requires inhibition of a bradykinin receptor.
9. Use according to Claim 8 wherein the bradykinin receptor is bradykinin B1 receptor.
10. The compound of formula (I) as claimed in Claim 1 or optical antipodes or racemates or pharmaceutically acceptable salt or hydrate or solvate thereof for use in the treatment and/or prevention of a condition which requires inhibition of a bradykinin receptor.
11. The use according to Claim 10 wherein the bradykinin receptor is bradykinin B1 receptor.